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Poor angiogenesis impairs bone regeneration, limiting the clinical translation of bone 
tissue engineered (BTE) grafts for the repair of large defects. In this project, 
vasculogenic endothelial progenitor cells (EPC) cocultured with osteogenic human 
fetal mesenchymal stem cells (hfMSC) potentiated its osteogenic differentiation in 
vitro through paracrine signalling and formed an in vitro vascular network in the three 
dimensional honeycomb polycaprolactone/tri-calcium phosphate composite scaffolds. 
Upon subcutaneous implantation, EPC/hfMSC showed enhanced vascularity and 
consequentially, improved osteogenicity in vivo. Biomechanical stimulation of 
EPC/hfMSC-grafts in a biaxial bioreactor resulted in increased cell viability, more 
robust bone formation and increased vasculogenesis compared to its implanted 
static-cultured coculture. In addition, the maintenance of hfMSC under continuous 
hypoxic microenvironment upon cell isolation demonstrated enhanced colony-
forming ability and osteogenic potential. This thesis explores the use of a coculture 
of stem cells, in conjunction with bioresorbable scaffolds, bioreactor technologies 
and a low oxygen microenvironment for the generation of voluminous bone grafts 
that are capable of rapid vascularisation for facilitating bone repair. 
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Chapter 1 – Introduction 
Happiness does not come from doing easy work but from the afterglow of 
satisfaction that comes after the achievement of a difficult task that demanded our 
best ~ Theodore Issac Rubin 
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Chapter 1 – Introduction 
1.1 Bone Grafts and Current Unmet Needs 
Bone is the second most transplanted tissue in the world, with the number of 
fractures per annum on the rise due to increasingly active lifestyles, accidents and 
aging. Recent advancements in new technologies for orthopaedic treatments of bone 
injuries have shown considerably favourable outcomes. However, in cases where 
there is extensive loss of bone due to trauma, post-tumour resection or inflammation, 
the repair for such large non-union fractures still remains a significant clinical 
problem. Globally, it has been estimated that approximately 15 million fracture cases 
occurs annually (O'Keefe and Mao 2011), of which up to 10% are complicated by 
non-union (Praemer et al. 1992; Salgado et al. 2004). Currently, most grafts utilised 
for bone repair suffer from a lack of integration with the host bone, and hence result 
in non-unions (Muramatsu et al. 2003; Soucacos et al. 2006)  with late graft fracture 
occurring as high as 60% at 10 years (Wheeler and Enneking 2005). Thus, there is 
an urgent need for new therapeutic strategies for bone repair to meet the increasing 
demand, with an estimated market potential of $3.3 billion by 2013 for bone grafts 
and its substitutes in the markets of United States alone (Frost&Sullivan 2007). 
 
1.2 Non-union Fractures 
In addressing the challenges faced by current clinical therapies for the repair of large 
bone defects, it is important to first understand bone physiology and the underlying 
reasons that result in these non-unions. Typically, non-unions are fractures that fail 
to heal after 6 months and can be caused by different factors including surgical 
expertise, pathological conditions and/or fracture types that vary between patients. 
Non-union fractures can be broadly categorised as hypertrophic, oligotrophic and 
atrophic non-unions which are primarily a result of insufficient mechanical 
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stabilisation, poor fracture apposition and poor vascularity respectively. Table 1-1 
compares the characteristics of both types of avascular and vascular non-unions and 
their associated strategy for successful bone repair. 
 
Table 1-1: Characteristics of the different types of non-union fractures include 
avascular and vascular non-unions (Tseng et al. 2008). Figure adapted from Mosby 
et al (Mosby 2003). 
Vascular Non-Union Avascular Non-Union 
Hypertrophic Oligotrophic 
• Lack of blood supply  
• No callus formation  
• No bone growth 
• Resorption at bone ends 
• Adequate blood 





• Minimal callus 
formation  
• Fracture fragments 
not properly 
apposed 
Require bone graft with 
vascularity 
 
Require external or 
internal fixation 
Require bone graft and 
proper fixation 
 
Eg. Comminuted (Necrotic 
fragment) 
 





1.3 Current Strategies for Bone Repair 
Currently, bone grafting strategies such as autologous grafts, allografts and synthetic 
grafts are used to address these clinical needs. Despite their widespread clinical 
utility, these strategies are subjected to limited success particularly for the repair of 
large bone defects. The advantages and disadvantages of each strategy are 
discussed in the next section. 
 





1.3.1 Autologous Grafts 
Autologous bone grafting is taking bone chips from a secondary site of the patient’s 
own body, with the iliac crest as the most common donor site, often taken in the form 
of trabecular bone. This remains as the gold standard for bone repair because it prov 
ides an osteoconductive matrix, osteogenic cells and an osteoinductive environment 
necessary for bone regeneration (Rose and Oreffo 2002) and will not cause any 
immunoreactions (Schroeder and Mosheiff 2011). However, a limited supply for 
harvest, donor site morbidity (Laurie et al. 1984), varying osteogenic graft potential 
depending on the age and health status of the patient, as well as the difficulty in graft 
shaping for filling of defect sites hamper its use. The need for two surgeries on the 
same patient also increases the cost and risk of infection (Fowler et al. 1995; Goulet 
et al. 1997; Tseng et al. 2008). 
 
1.3.2 Allogenic Grafts 
To overcome issues of harvesting and limited tissue quantities, allografts have been 
used as an alternative, where bone is taken from another patient’s body. However, 
this strategy introduces possibilities of potential graft rejection by the host immune 
system and disease transmission from donor to host (Rose and Oreffo 2002). The 
use of allografts have also been reported to result in poorer bone healing due to 
reduced cellularity and vascularity upon processing (Damien and Parsons 1991; 
Lane et al. 1999) and do not provide the necessary osteoinductive signals upon 
sterilisation as compared to autologous grafts (Oklund et al. 1986). Other 
complications of allografts segments are associated with incomplete resorption, 
resulting in fatigue failure and infections (Thompson et al. 1993).  
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1.3.3 Synthetic Grafts 
Synthetic grafts such as metals and ceramics are subjected to fatigue, fracture, 
toxicity and wear over time, without the possibility of remodelling which is a critical 
part of the bone healing process (Salgado et al. 2004). Metals for example, have 
excellent mechanical properties but are unable to integrate with the host bone. 
Ceramics are brittle and has a high Young’s modulus (Teoh 2004) and low tensile 
strength, thus not suited for use in locations that undergo significant torsion, bending 
or shear stress (Yaszemski 1994).  
 
1.4 Bone Tissue Engineering  
To overcome the issues encountered in current strategies, bone tissue engineering 
(BTE) has emerged as an alternative for fracture repairs. Tissue engineering is “an 
interdisciplinary field of research that applies the principles of engineering and the 
life sciences towards the development of biological substitutes that restore, maintain, 
or improve tissue function’’ (Langer and Vacanti 1993). Briefly, this strategy involves 
an appropriate combination of cells and their biomolecules such as growth factors, 
scaffolds, bioreactor culture systems, allowing for intercellular communications and 
cell-biomaterial interactions towards achieving a therapeutic response. This will be 
accompanied by various imaging tools to determine the success of the tissue 




Figure 1-1: Four key technologies used in tissue engineering include cells and their 
biomolecules, scaffolds, bioreactors and imaging tools. 
 
1.4.1 Limitations in Bone Tissue Engineering 
Since the introduction of BTE over the past two decades, there has been an 
exponential increase in the number of investigations in the area of BTE, with close to 
10,000 publications and more than 200,000 citations in this growing field (Figure 1-
2; Web of Science, 2012). 
 
 
Figure 1-2: Graphical analysis of the total number of publications and citations on 








Total publications: 9789 Total number of 
times cited: 219124 
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Despite several groups having reported considerable success in their approach in 
the regeneration of bone in various animal segmental models (Bruder et al. 1998; 
Arinzeh et al. 2003; Zhu et al. 2006; Rai et al. 2007; Bae et al. 2011; Kolambkar et al. 
2011), few have reported clinical success (Meijer et al. 2007). Current BTE 
constructs suffer from a lack of sufficient vascularity within larger grafts due to slow 
spontaneous vessel ingrowth (Clark 1939), hence resulting in cellular necrosis 
especially at the core and eventual failure of the BTE graft over time (Ko et al. 2007). 
A pilot cell-based clinical study for the treatment of large bone defects (Quarto et al. 
2001) has shown vascularisation in the grafted region at 6.5 years post-surgery 
(Marcacci et al. 2007). However, most studies still lack clear data demonstrating 
evidence of early vasculature development within the graft necessary for cell survival, 
and eventual integration and long term remodelling. Therefore, apart from ensuring 
the converging use of osteoconductive matrices, osteoinductive signals and 
osteogenic cells in sufficient numbers, ensuring an adequate vascular supply is 
crucial for successful bone repair in large defects. Challenges relating to achieving 
adequate vascularisation within synthetic bone grafts remain a major concern 
(Cancedda et al. 2007), hence limiting the introduction of BTE into the clinical setting.   
 
1.5 Importance of Vascularisation 
1.5.1 Vascularisation in Bone Tissue Engineering 
The importance of angiogenesis has been documented as early as the 1700s by 
Hunter (Haller 1763) and Haller (Hunter and Palmer 1840), but was however not 
recognised as an important aspect of bone healing until the 19th century where 
Trueta suggested that “vascular stimulating factors” present at the sites of bone 
damage initiate osteogenesis (Trueta and Buhr 1963). This has since been verified 
by many experimental studies which demonstrate a need for an adequate vascular 
supply in order for bone regeneration to succeed (Carano and Filvaroff 2003; 
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Kanczler and Oreffo 2008). For example, endogenous vascular endothelial growth 
factor (VEGF) has been shown to be essential for endochondral bone formation 
(Gerber et al. 1999; Street et al. 2002; Zelzer et al. 2002). Inhibition of VEGF via a 
soluble neutralising VEGF receptor during endochondral and intramembranous 
ossification led to decreased angiogenesis, with reduced callus mineralisation and 
bone formation in a femoral fracture and tibia cortical bone defect in mice 
respectively (Figure 1-3A). Conversely, an exogenous VEGF supply accelerated 
bone bridging across a critical-sized defect (CSD) in rabbit radius, suggesting the 
distinct roles of VEGF as an angiogenic factor in promoting bone healing (Figure 1-
3B) (Street et al. 2002). Optimal healing of the defect region is found to be heavily 
reliant upon adequate vascularisation, hence suggesting the integral role of blood 
vessels for bone regeneration.  
 
A. Mice femur defect B. Rabbit segmental defect 
  Control               Flt-IgG                IgG 
 
       Placebo              VEGF (250µg)   
 
Copyright (2002) National Academy of Sciences, U.S.A. 
 
Figure 1-3: Three-dimensional rendering of computed tomography scans. (A) Mice 
femurs showed impairment of fracture repair upon soluble, neutralising VEGF 
receptor (Flt-IgG) treatment as compared to its controls after 7 days.  Callus (blue) 
and cortical bone (peach). (B) VEGF stimulated repair of a rabbit segmental defect 
upon exogenous VEGF-treatment (250µg) compared to its placebo on 28 days. 
Figures reproduced from Street et al (Street et al. 2002). 
 
1.5.2 Vascularisation in Natural Bone Repair Processes 
In the natural physiology, bone repair processes such as endochondral and 
intramembranous ossification occur in the proximity of a vascular network. Briefly, 
endochondral bone formation develops via a cartilage model where subsequent 
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osteogenesis and mineralisation of the cartilaginous callus relies on the extent of 
vascularisation. This process will be discussed in greater detail in Chapter 2. In 
comparison, intramembranous ossification is a non-cartilaginous process that is 
involved in the natural healing of bone fractures. Here, the presence of blood vessels 
is necessary for directing the differentiation of mesenchymal stem cells into 
osteoblasts at the fracture site (Kanczler and Oreffo 2008).  
 
1.5.3 Periosteum and Its Vasculature  
The periosteum, a highly vascularised thin bilayered tissue membrane covering the 
bone surfaces, is also found to play a crucial role during fracture healing (Bullens et 
al. 2010). The highly vascularised periosteum consists of a network of 
microvasculature resides in the outer fibrous layer of the periosteum which is known 
as the intrinsic periosteal system (Simpson 1985). Other periosteal-associated 
vessel systems includes the musculoperiosteal and fascioperiosteal vessels which 
connect the muscles and periosteum (Colnot 2009), while the cortical capillary 
anastomoses are linked to the intramedullary circulation in the bone cortex (Simpson 
1985).  
 
During a fracture, the outer cambium layer of the activated periosteum is responsible 
for driving the initiation of osteogenesis and angiogenesis for bone repair, and direct 
the differentiation of stem cells into bone lineage (Tran Van et al. 1982). 
Experimentally, the osteogenic and angiogenic potency of the periosteum has been 
investigated in various in vitro and in vivo studies, showing revitalisation of allografts 
or enhancement in bone regeneration (Melcher and Accursi 1971; Tran Van et al. 
1982; Jacobsen 1997; Lemperle et al. 1998; Runyan et al. 2010). Conversely, the 
absence of a periosteum in fracture healing was demonstrated to result in decreased 
fracture healing capacity (Utvag et al. 1996; Ozaki et al. 2000; Colnot 2009; Bullens 
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et al. 2010). For example, Shimizu et al reported no new bone formation when 
periosteum was removed completely from the rat calvarial bone, while new bone was 
observed on the parietal bone surface on Week 3 in areas in direct contact with the 
periosteum (Shimizu et al. 2001).  
 
From the natural physiological repair of the bone tissue and its anatomy, it is evident 
that blood vessels play an integral role for bone regeneration and the optimal healing 
of the defect region is heavily reliant upon adequate vascularisation.  
 
1.6 Motivation of Study 
Existing solutions do not adequately address the limited neovascularisation in 
voluminous BTE-grafts for the repair of large bone defects. This results in insufficient 
nutrient and oxygen supply, high cellular death and consequential graft failure. 
Hence, there is an urgent unmet need for an effective tissue-engineered solution to 
treat CSD. To overcome current issues with vascular insufficiencies in these artificial 
grafts, various vascularisation strategies have been developed (Rouwkema et al. 
2008). The importance of vascularisation and the vascularisation strategies used in 
































Figure 1-4: Vascularisation as a key component for successful BTE as well as other 
areas of tissue engineering where vascularisation is needed. 
 
Compared to traditional BTE approaches, vascularisation will be the key component 
for investigation in this project (Figure 1-4). The main aim is to generate a highly 
vascularised and osteogenic bone graft, with the intention of facilitating fracture 
healing in a large bone defect and allow for host integration and remodelling over the 
long term. 
 
1.7 Proposed Approach  
1.7.1 Vascularised BTE – A Mimicry of Natural Bone Tissue 
In this project, my proposed BTE approach will be designed in close mimicry to the 
physiological microenvironment of the natural bone tissue. I will leverage on the 
osteogenic differentiation capacity of human fetal MSC (hfMSC) and the 
vasculogenic capacity of umbilical cord blood-derived EPC (UCB-EPC). Other 
specific considerations of the various BTE components includes the type of dynamic 
bioreactor culture, scaffold material and its architecture, as well as the 
microenvironment of oxygen tension, biomechanical and biochemical cues. Table 1-
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2 summarises my proposed BTE approach and the individual BTE components, as 
well as its relation with the natural bone. Detailed justification of the proposed BTE 
approach will be discussed in the next chapter. 
 
Table 1-2: Proposed BTE approach and the choice of each individual BTE 

























t Coculture of 
mesenchymal stem 

























oxygen tension in 
bone marrow niche 
(2-8%) 
 
1.7.2 Aims and Hypotheses 
1.7.2.1 Main Aim 
This project aims to generate highly vascularised and osteogenic bone grafts using a 
coculture of stem cells, scaffold and bioreactor technologies through rapid 
vascularisation and osteogenic strategies for facilitating eventual fracture healing in a 










1.7.2.2 Hypothesis 1 
Incorporation of EPC in coculture with hfMSC improves vascularity and 
consequential cellular survival and osteogenicity, leading to improved bone healing. 
1.7.2.3 Hypothesis 2 
Bioreactor culture induces early neovasculogenesis of EPC, accelerates 
vascularisation and enhances osteogenic differentiation of hfMSC, leading to 
improved bone repair. 
1.7.2.4 Hypothesis 3 
Exposure of hfMSC and EPC to a hypoxic microenvironment mimicking that of the 
natural physiology promotes the osteogenic differentiation and vessel-forming ability 
of the monocultures respectively. 
 
1.7.3 Novelty and Clinical Implications 
It is now clear that poor vascularisation of a tissue graft remains a major challenge in 
inducing effective fracture healing and thus, a major thrust in this project. The 
interactions of vasculogenic EPC and osteogenic hfMSC will be interrogated for their 
synergistic effects when in coculture in both in vitro and in vivo experiments and how 
it leads to increased vascularisation and bone formation. This work will enhance the 
understanding of the specific interactions between the two cell types which are 
involved in the natural repair of skeletal injuries. 
 
In addition, the specific interactions of the coculture with a dynamic bioreactor culture 
and low oxygen tensions will be investigated in relation to their contributions towards 
building an efficacious vascularised bone graft. Currently, the use of biomechanical 
stimulation in current coculture studies is often neglected, likely to be essential for 
the maturation and long term efficacy of these bone grafts upon clinical translation. 
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There is also a lack of understanding on the importance of microenvironment oxygen 
tensions on stem cell fate. Results should identify if there is a need to revolutionalise 
conventional cell culture techniques where stem cells are grown under atmospheric 
21% oxygen as compared to the low physiological oxygen tensions in the bone 
marrow niche. Successful demonstration of effective vascularisation and bone repair 
of a CSD model in a large animal model should present viable options for more 
















Chapter 2 – Literature Review 
Do not follow where the path may lead. 
Go instead where there is no path and leave a trail.  
~Ralph W. 
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Chapter 2 – Literature Review  
2.1 The Skeletal System 
The adult human skeletal system performs many functions. It provides a structural 
support to the body and protects vital organs such as the brain, lungs and heart. 
Bones work in synchrony with muscles to allow for movement and locomotion. The 
skeleton also acts as a store for minerals such as calcium and phosphorus, 
maintaining bone homeostasis and ensuring an acid-base balance. In larger bones, 
it provides an environment for haematopoiesis within the marrow (Clarke 2008).  
 
The skeleton comprises of a total of 213 bones, excluding sesamoid bones which 
are embedded within a tendon. These bones are generally categorised into four 
groups – the long bones, short bones, flat bones and irregular bones (Clarke 2008).  
 
2.2 Anatomy of Bone  
The human skeletal system consists of 80% cortical bone and 20% spongy bone 
overall, with varying ratios depending on the skeletal site and type of bone (Eriksen 
et al. 1994). Cortical bone is a dense and solid tissue with only 10% porosity, hence 
providing the bulk of strength to the skeletal system (Sikavitsas et al. 2001). The 
spongy bone has a honeycomb structure consisting of branching rods and plates of 
varying sizes, with a porosity of 50-90%, hence keeping bone light (Figure 2-1). 
However, its mechanical properties (modulus and ultimate compressive strength) are 




Figure 2-1: Anatomy of the long bone and microstructure of vascularised bone 
tissue and the comparative porosity of compact bone and spongy bone. Figures 
reproduced from U.S. National Cancer Institute’s Surveillance, Epidemiology and 
Eng Results (SEER) Program (U.S. National Cancer Institute’s Surveillance 2012; 
U.S. National Cancer Institute’s Surveillance 2012). 
 
Long bones have a long and hollow diaphysis shaft which is flared slightly at the 
metaphyses below the growth plates and rounded at its epiphyses ends above the 
growth plates. Cortical bone surrounds the entire bone and primarily occupies the 
marrow space at the diaphysis, where Haversian systems (osteons) constitute the 
basic structural unit of the cortical bone. They are cylindrical in shape with concentric 
layers of lamellae surrounding a central canal, known as Haversian canals. These 
Haversian canals, connected to the periosteum and endosteum via the Volkmann’s 
canals, contain the bone’s nerve and blood supply at a flow rate of 200-400ml/min in 
adult humans (Gruber 2008). This high level of vascularity in bone is necessary for 
the maintenance of cellular survival, active remodelling and skeletal integrity. 
Compared to compact bone, the trabecular bone has a higher surface area and 
constitutes largely the inner region of the epiphysis and metaphysic (Eriksen et al. 
1994; Deng and Liu 2005; Gruber 2008). The periosteum surrounds the outside of 
bone except at areas covered by the articulating cartilage, and the endosteum lines 
the inner bone surface within the marrow. 
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Examination of the anatomy of bone also reveals a complex hierarchical structure, 
starting from the sub-nano level of molecules and minerals, where collagenous 
proteins are arranged in fibrillar bundles that form lamellae on the sub-micron level. 
The microstructure of bone comprises of the Haversian systems, osteons and layers 
of lamellae, forming the macrostructure of cortical and cancellous bone (Figure 2-2) 
(Rho et al. 1998).  
 
Figure 2-2: A schematic of the hierarchical structure of bone from a sub-
nanostructure of collagen molecules to a nanostructure of cylindrically arranged 
microfibrils to lamellar layers forming the macrostructure of cortical bone. Figure 
adapted from Rho et al (Rho et al. 1998).  
 
2.3 Composition of Bone 
2.3.1 Bone Cells 
The maintenance of bone as a dynamic living tissue results from the interaction of 
various cell types, each with a defined function. Bone cells can be classified into five 
main cell types (Deng and Liu 2005; Clarke 2008; Gruber 2008): 
 
(1) Osteoblasts are bone-forming cells are located on the surface of mineralised 
matrix. They are differentiated from mesenchymal stem cells, incapable of 
























serves as a template for mineralisation to occur. Upon cessation of matrix 
formation, osteoblasts can undergo apoptosis, fully differentiate into osteocytes 
or remain inactive as lining cells on the surface of bone.  
 
(2) Osteocytes are fully differentiated mature osteoblasts that are unable to divide. 
They have a stellate morphology and are trapped singly within the tiny lacunae 
spaces and embedded within the osteoid. They connect and communicate with 
other bone cells through cytoplasmic protrusions, forming a network of canaliculi. 
Osteocytes also act as mechanosensors and adapt bone to functional loading 
during remodelling. They also maintain metabolism by regulating mineral content 
and play a role in bone turnover. 
 
(3) Osteoclasts are large multinucleated cells located within bone that are involved in 
bone resorption. They come from a haematopoietic origin, derived primarily from 
the fusion of monocytes. They are highly motile and are mostly found at sites of 
high bone turnover, along the surface of bone.  
 
(4) Osteogenic cells are immature bone cells found in the inner surface of 
periosteum, endosteum, within Haversian canals, capable of differentiating into 
osteoblasts and osteocytes. 
 
(5) Bone lining cells are quiescent osteoblasts that line the surface of bones. Their 
role is to regulate mineral content such as calcium and phosphate in the bone.  
 
2.3.2 Bone Matrix 
Bone is a composite material made of a mineral phase and an organic phase. It is 
this matrix composition that gives rise to the unique properties of bone. The mineral 
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phase comprises largely of hydroxyapatite, providing the bulk of the tensile yield 
strength and plays an important in the storage of various ions. The mineral salts of 
bone comprises of largely of calcium and phosphorus (Downey and Siegel 2006). 
The organic phase is composed of 90% Type 1 collagen as the main structural 
element with the remaining consisting of non-collagenous proteins, mainly 
glycoproteins and proteoglycans.  
 
2.4 Natural Bone Forming Process 
Bone is a self-reparative tissue, capable of complete regeneration and remodelling 
without leaving a scar (Sommerfeldt and Rubin 2001). In designing appropriate 
strategies for accelerating fracture healing, the natural spontaneous bone healing 
process needs to be understood. In Section 1.5.2, the two main processes of bone 
formation, namely endochondral and intramembranous ossification were briefly 
discussed in relation to their need for vessel formation. Here, the processes of 
endochondral ossification and distraction osteogenesis, which primarily undergoes 
intramembranous ossification, will be examined in greater detail. 
 
2.4.1 Endochondral Ossification 
Endochondral ossification is a process by which bone grows via cartilaginous 
formation as an intermediate stage. It undergoes four main stages – (1) Inflammation, 
where a haematoma forms and stabilises the fracture ends; activates a cascade of 
cellular events which recruits various cell sources to the fracture area, including MSC. 
(2) Soft callus (cartilage) develops as MSC and other bone forming cells differentiate 
into chondrocytes and proliferate, synthesising a cartilaginous extracellular matrix. 
(3) Blood vessels invade and the cartilaginous regions undergo resorption and 
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mineralise, forming woven bone that (4) ultimately remodels into lamellar structure 
over time (Table 2-1). 
 
Table 2-1: Endochondral ossification involves four main stages, namely the 
inflammatory phase, soft callus fibrocartilageous formation, hard callus formation and 
bone remodelling (Lieberman and Friedlaender 2005).  





• Release of cytokines  
• Dead cells removed by osteoclasts 
• Movement of fracture fragments stops 
osteoblast activity and blood flow 
• Haematoma formation linking bone 
fragments 
• Recruitment of fibroblasts, MSC 
• Granulation tissue formation 
 
3 to 5 days 
Soft callus formation 
 
• Cartilage formation and endochondral 
ossification occurs 
• Weak to external stresses 
• Sufficient stability for vessels to form 
• Vasculogenesis and angiogenesis 
 
4 days to 3 
weeks 
Hard callus formation 
 
• Cartilage resorbs and mineralises 
• Woven bone formation 
• Fracture union achieved 




• Normal bone shape restored 
• Continuous resorption and bone formation 
throughout lifetime 
• Lamellae bone formation 
Up to several 
years 
 
2.4.2 Distraction Osteogenesis 
Distraction osteogenesis is one surgical method where induction of natural bone 
formation is observed, and its predominant mechanism is via intramembranous bone 
formation where an adequate blood supply is present (Delloye et al. 1990; White and 
Kenwright 1990). It is used primarily for reconstruction of skeletal deformities or 
defects secondary to trauma, infection or bone resection, and for bone lengthening 
to fix length discrepancies. An osteotomy is first performed to fracture bone into two 
pieces, and the two vascularised bone surfaces are gradually pulled apart by tensile 
forces at a fixed rate and timing. The longitudinal mechanical strain exerted on the 
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callus during the distraction phase initiates biological responses that stimulate the 
formation of mineralised bone, followed by eventual remodelling (Ai-Aql et al. 2008). 
During this regenerative process, bone is formed at a rate of 200-400µm/day. The 
histological representation of each stage during distraction osteogenesis is as 
illustrated in Table 2-2 below. 
 
Table 2-2: The process of distraction osteogenesis involves three stages, namely 
latency, distraction and consolidation. Figures reproduced from Ai-Aql et al (Ai-Aql et 




Histology taken on Day 7 
post-surgery 
• Osteotomy of bone 
• Hematoma formation  
• Inflammatory process occurs as per fracture repair 
• Recruitment of MSC 
• Soft callus and cartilage formation  
Active distraction 
 
Histology taken on Day 10 
post-surgery 
• Tensile forces applied to callus (rate of 1mm/day) 
• Cartilage resorps and forms endochondral bone 
• Fibrous interzone forms (Rich in chondrocyte-like 
cells, fibroblasts, and oval cells) 
• Angiogenesis 
• Osteoblasts recruited and differentiated, forming 
bone columns (intramembranous bone) 
• Distraction ceases upon desired bone length  
Consolidation 
 
Histology taken on Day 31 
post-surgery 
• Bone columns connect 
• Osteoclast recruited 
• Bone and osteoid mineralises and remodels 
 
2.5 Physiological Microenvironment of Bone 
Looking at the physiological environment of bone, there are various 
microenvironment cues involved in facilitating bone formation and repair, of which 
includes biomechanical, biochemical and oxygen tension cues. It is therefore 
essential to consider these microenvironmental cues during the process of 





Figure 2-3: Vascularised bone anatomy and microenvironmental influences such as 
biomechanical, microarchitectural and low oxygen tension cues. 
 
2.5.1 Biomechanical Cues 
There are various biomechanical cues involved in this process of bone formation and 
remodelling. During daily activities, the human skeletal system experiences various 
biomechanical forces, including compressive, bending and torsional loads 
(Shelburne et al. 2005). On a microscopic level in bone, strain is experienced due to 
tissue deformation. Fluid shear stresses is also exerted by interstitial fluid flow 
through the lacunae, driven largely by compression and tension under loading onto 
the bone (McCoy and O'Brien 2010). Bone, as a dynamic living tissue, undergoes 
remodelling where it continuously gets resorbed and deposits new bone concurrently 
during physiological homeostasis in the lifetime of an individual. Early observations 
showed that this process could be adapted by mechanical stimuli, where Wolff’s Law 
(1892) states that bone adapts its structure and remodels accordingly to mechanical 
loads (Wolff 1892). Although the influence of the mechanical transduction pathway 
on bone cells during adaptive remodelling is poorly understood, it has been well-
demonstrated that mechanical stress favours the formation of bone as opposed to 
bone loss which happens under non-weight bearing circumstances such as in space 













concept has been proposed by Davis (1953) stating that the remodelling efficacy of 
soft tissues is based on imposed demands (Henenfeld 1953). Putting Davis’ Law into 
perspective during bone formation, the induction of bone formation in distraction 
osteogenesis relies on mechanical stimulus (tensile forces) as the osteotomised 
bone ends are gradually distracted, with new bone being deposited within the 
enlarging gap. The longitudinal mechanical strain exerted on the callus during the 
distraction phase then initiates biological responses that stimulate the formation of 
mineralised bone and eventual remodelling (Ai-Aql et al. 2008).  
 
Biomechanical cues are also relevant in vascular physiology in the bone, where the 
endothelial cells in blood vessels are constantly exposed to blood flow tangential to 
the endothelial monolayer. This is essential in controlling many aspects during the 
fate of an endothelial cell, including the mediation of transcriptional changes, 
endothelial sprouting (Song and Munn 2011), proliferation (Lin et al. 2000) and 
vessel homeostasis (Hudlicka et al. 2006; Jones et al. 2006). The profound effects of 
biomechanical forces for stimulating vessel and bone formation and remodelling 
have also been well demonstrated experimentally (Ehrlich and Lanyon 2002; 
Yamamoto et al. 2003; Yamamoto et al. 2005; McCloskey et al. 2006; Grellier et al. 
2009; Stolberg and McCloskey 2009; Kimelman-Bleich et al. 2011).  
 
2.5.2 Oxygen Tension Cues 
During a fracture, the vascular supply gets disrupted, resulting in a hypoxic 
environment. This acts as a stimulus for the upregulation of various angiogenic 
factors towards forming a vascular network. The mechanisms of vessel formation 
occur via activation of the hypoxia-inducible factor (HIF) pathways upon ischemia 
during a fracture. Ischemia at sites of injured tissues would mobilise cells which 
migrate towards the site for repair. The master control in the trafficking of these cells 
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is a result of the activation of the HIF-1 pathway, triggering the upregulation of a 
series of angiogenic factors such as VEGF and the Angiopoietins (Figure 2-4A) 
(Germain et al. 2010). The generation of a concentration gradient of growth factor 
instructs the migration of endothelial cells, with its tip cells acting as oxygen sensors 
to guide vascular invasion into hypoxic zones, while its stalk cells proliferate, hence 
forming a vascular network (Figure 2-4B) (Coulon et al. 2010; Germain et al. 2010). 
It is the molecular mechanisms induced by the hypoxia-activated master switch HIF-
1α, 2α that are involved in assisting vessel formation and stabilisation respectively 
(Coulon et al. 2010). It has been demonstrated that HIF-1α stimulates 
neovascularisation and improves functional recovery in ischemic tissues of various 
animal models (Vincent et al. 2000; Jiang et al. 2008; Li et al. 2011) as well as  
promotes the recruitment and homing of bone marrow progenitors to these ischemic 
sites (Ceradini et al. 2004; Du et al. 2008). 
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Figure 2-4: (A) Under hypoxic conditions, the HIF-1α subunit accumulates and is 
stabilised, allowing it to translocate into the nucleus for dimerisation with the HIF-1β 
subunit, forming the HIF-1 complex. This initiates the upregulation of several 
angiogenic genes and secretion of growth factors. Figure reproduced from Carmeliet 
and Jain (Carmeliet and Jain 2000). (B) Sprouting of the endothelial cells is induced, 
resulting in tip cells migrating towards the hypoxic stimulus, with stalk cells following 
behind. New vascular network forms with the emergence of various branch points 
overtime. Figure reproduced from Wood et al (Wood 2011).  
 
2.5.3 Biochemical Cues 
The natural fracture healing process is also regulated by a milieu of growth factors 




BMPs and TGFs belonging under the TGF-β superfamily are known for their 
important contributions in regulating mineralisation and bone formation (Wozney 
1989; Chen et al. 2004), while angiogenic factors such as VEGF and angiopoeitins 
are critical for directing angiogenesis (Schott and Morrow 1993; Ribatti et al. 2000). 
Various molecular regulators such as inflammatory, osteogenic and angiogenic 
factors have been identified at different stages of bone repair and described to be 
expressed in a sequential and temporal fashion at varying levels (Ai-Aql et al. 2008) 
(Table 2-3A).  
 
The vascularised microenvironment of bone and their corresponding biomechanical 
and biochemical cues involved during natural bone repair is summarised in Table 2-
3B.  
 
Table 2-3: (A-B) Comparison between the natural fracture healing and distraction 
osteogenesis processes and their various microenvironmental cues that contribute to 
vascular and bone formation, including the relative up and down expressions of 
molecular regulators involved in various stages of bone repair and distraction 
osteogenesis. Table 2-3A reproduced from Ai-Aql et al (Ai-Aql et al. 2008).  
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A. 




 Fracture Repair (Endochondral Ossification) Distraction Osteogenesis 
Stages • Haematoma formation 
• Cartilage formation 
• Vascular infiltration 
• Primary bone formation 
• Secondary bone formation and remodelling  
• Latency  




and role of 
vasculature  
• Mineralisation of the cartilaginous callus region relies on 
the extent of vascularisation 
• Blood vessel invasion required to recruit and differentiate 
MSC into osteoblasts  
• Bone is osteotomised into two pieces; periosteum and 
medullary vessels remain intact 
• Bone pieces pulled apart while bone forms in gap   
Biomechanical 
Induction 
No induction except for physiological interstitial flow and 
mechanical loading arising from daily activities 






































































































































































































































2.6 Bone Tissue Engineering 
2.6.1 Four-Stage Bone Formation in Bone Tissue Engineering 
In Section 1.4, the four key technologies such as cells, scaffolds, bioreactors and 
imaging tools that are used in BTE has been discussed. In addition to designing 
successful BTE constructs, strategies should be directed towards achieving mature 
bone with a more oriented bony structure associated with at least moderate 
mechanical properties. Current BTE strategies often report success in the formation 
of early-stage bone, with few demonstrating late-stage bone. To track the stage of 
maturity of bone formation during BTE, the progression of bone formation has been 
categorised into four distinct stages, starting from the precipitation of mineralised 
nodules to eventual lamellar bone formation (Table 2-4). 
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Table 2-4: Four-staged bone forming process relating to the structural bone, its mechanical properties and vessel formation over time of 
healing; + indicates the relative intensity. 
Stage 1 Stage 2 Stage 3 Stage 4 Stage of 
Bone Formation Mineralisation Woven bone Trabecular bone Lamellae bone 
Mechanical Strength + ++ +++ ++++ 
Bone Structure Random distribution 
 
Nucleation and rapid growth 
of mineral nodules occurs 
under a thermodynamic 
driving force when in a 3D 
space 
Disjointed fine plate-like 
networks of two or more 
connecting fibres randomly 
oriented 
Low density with large 
porosity 
Bone plates are joined and 
highly oriented, conforming 
to the applied stresses 
Dense and compact 
Multilayered bone plates 
arranged in a concentric 
manner conforming to 
applied stresses 
 
(Barbashina et al. 2004)  (Ribó 2011) (Meijer et al. 2007) 
 Time from injury 1-2 weeks 3-6 weeks ~3-6 months Months-Years 
Vascularisation 
    
(a) Extraosseous + +++ +++ +++ 
(b) Medullary - + ++ +++ 
Cytokines Discontinuous and temporally regulated at high levels Moderate regulation for homeostasis and remodelling 
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2.6.2 Strategies in Bone Tissue Engineering 
BTE strategies can be broadly categorised into two main approaches, namely the 
growth factor and cell-based approach. The growth factor approach is simple and 
relies on the mobilisation of the patient’s own stem cells for self-reparative bone 
healing mechanisms, hence avoiding all issues pertaining to cell culture and 
expansion. However, this technique might not be beneficial to the aged or patients 
suffering from severe trauma, poorly controlled diabetes, and osteoporosis due to 
their diminishing pool of endogenous osteogenic cells (Bruder and Fox 1999; Service 
2000). On the other hand, a cell-based approach utilises an exogenous supply of 
osteogenic cells in sufficient numbers for direct bone repair. 
 
2.6.2.1 Growth Factors Approach 
One strategy utilises growth factors which are commonly used as signalling 
molecules for the stimulation of cellular growth, proliferation and differentiation. The 
use of growth factors for bone regeneration has been reported with some success in 
various animal and clinical models (Luginbuehl et al. 2004; Lee et al. 2011). 
However, the intrinsic instability of growth factors and short half-life leads to rapid 
loss in bioactivity upon release in vivo (Tabata 2003). To attain a therapeutic effect, a 
high supraphysiological dosage is often used, raising concerns of possible risks of 
overriding the normal regulation of osteoinduction. To overcome this problem, 
delivery systems are used in conjunction with growth factors for controlled sustained 
delivery through non-covalent or covalent entrapment methodologies (Figure 2-5) 








Figure 2-5: Growth factor delivery systems and their various entrapment 
methodologies. Non-covalent strategies include (A-C) physical entrapment released 
by diffusion with or without degradation of delivery system (D-E) adsorption through 
physiochemical interactions with material or receptor-proteins (F) ion complexation of 
growth factors with oppositely charged molecules or via (G) covalent means through 
direct coupling or via a bifunctional linker. Figures reproduced from Luginbuehl et al 
(Luginbuehl et al. 2004). 
 
To note, these growth factor delivery systems release growth factors on a continuous 
burst release profile. Hence, it is difficult to control the temporal and spatial release 
profile of growth factors in a way that mimics the physiological up and down-
expression of cytokine response during different stages in bone repair as discussed 
in the earlier section (Ai-Aql et al. 2008). Furthermore, the lack of information on the 
optimal concentrations and controlled time of release makes delivery of multiple 
growth factors difficult. Apart from the high costs, recent issues relating to the safety 
and long term efficacy of growth factors have also been highlighted (Poynton and 
Lane 2002). For example, bone morphogenetic proteins (BMPs) are potent bone-
stimulating growth factors, of which BMP-2 and BMP-7 are FDA-approved for the 
treatment of long bone non-union fractures and spinal fusions. However, recent off-
label use of bone morphogenetic protein (BMP) for lumbar interbody fusions have 
resulted in ectopic bone formation associated with severe neurological impairment 
(Wong et al. 2008); other adverse complications arising from BMP use include 
excessive swelling at neck and throat, breathing and swallowing difficulties (Shields 
et al. 2006; Boraiah et al. 2009). Thus, the use of the growth factor requires much 
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caution and is deemed less ideal as a therapeutic modality for BTE applications. 
Better understanding of growth factors including the appropriate dosage, mode of 
administration as well as other clinical trial design-related issues is required (Lee et 
al. 2011). 
 
2.6.2.2 Cell-Based Approach 
The first cell-based approach using unfractionated fresh bone marrow was 
implemented in 1989 (Connolly 1989), with  other cell sources such as 
undifferentiated stem cells and differentiated osteoblasts also being used and 
reported with some success in various experimental animal models (Tseng et al. 
2008) and in the clinical realm (Salter et al. 2011). Compared to the growth factor 
strategy, a cell-based strategy has the inherent ability to secrete a milieu of growth 
factors at its physiological doses and timings that is likely to be more conducive for 
tissue regeneration compared to the growth factor approach (Rouwkema et al. 2008). 
However, stringent regulatory approvals of cellular therapy also warrant greater 
caution when used in the clinics. 
 
This PhD project will focus on a cell-based strategy for vascularised BTE due to the 
reported clinical efficacy in various cell-based therapies (Zhang et al. 2012). 
 
2.7 Vascularisation Strategies in Bone Tissue Engineering 
Keeping in mind the extensive vasculature within the natural bone tissue, bone is 
heavily reliant on this supply of blood vessels for maintenance of cell survival and 
skeletal integrity. Generally, tissues rely on blood vessels within close proximity of 
100-200µm to supply sufficient nutrients and oxygen (Carmeliet and Jain 2000). 












been limited to thin or avascular tissues such as skin and cartilage respectively, 
while vascular insufficiency exists in other thick tissues and voluminous tissue-
engineered grafts. In times of a bone fracture, the vascular supply in the defect zone 
is disrupted. Slow spontaneous vascular ingrowth is inadequate (Rouwkema et al. 
2008). Hence, large BTE-grafts often suffer from poor cellular survival particularly in 
the core due to inadequate exchange of nutrient and oxygen (Figure 2-6) 
(Rouwkema et al. 2008). This results in non-uniform cell integration, cellular necrosis 
and eventual failure of the BTE-graft (Ko et al. 2007; Kanczler and Oreffo 2008; 
Rouwkema et al. 2008), limiting the clinical translation of tissue engineering research. 
Muschler’s theoretical model illustrates the oxygen concentration gradient within a 
cellular-scaffold graft, where cell survivability is based on a balance between cellular 
density, their oxygen consumption as well as diffusion distance within the scaffold 
(Muschler et al. 2004). To approach this issue, several strategies have been 
undertaken to introduce vasculature into tissue-engineered constructs (Rouwkema et 

















Figure 2-6: Conceptual illustration of cell viability and cell death within the thick 
scaffold graft towards its core where cells are found more than 200µm away from the 
blood vessel supply.  
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2.7.1 ‘Smart’-scaffolds and Growth Factors 
One strategy involves the use of ‘smart’-scaffold technology by functionalising 
scaffolds surfaces through physical adsorption via intermediate proteins or biological 
molecules or by direct covalent immobilisation of bioactive molecules such as growth 
factors. Growth factors can also be physically encapsulated within the scaffolds, 
acting as delivery systems for controlled release (Lee et al. 2011) (Figure 2-7). For 
example, VEGF covalent linked-collagen scaffolds resulted in rapid vascularisation in 
vivo, leading to improved myocardial repair compared to its untreated control. In 
another study, Kaigler showed increased blood vessel formation invading the VEGF-
encapsulated poly(lactic-co-glycolic acid) scaffolds, accompanied by earlier and 
greater bone formation in an irradiated rat calvarial defect model compared to 
scaffolds alone (Kaigler et al. 2006). In gene therapy, stem cells such as MSC are 
used as vehicles for the delivery of angiogenic growth factors, where cells are 
transduced ex vivo, encoding the growth factor/s of interest. For example, the use of 
VEGF-transduced MSC showed increased vascularity upon VEGF expression alone, 
which in synergy with VEGF/bone morphogenetic protein-2 (BMP-2) transduced 
MSC enhanced bone formation in a segmental tibia defect mice model (Kumar et al. 
2010). Numerous other studies have also demonstrated significant benefits of 
angiogenic growth factor delivery (Street et al. 2002; Kempen et al. 2009) or gene 




A.            B. 








Figure 2-7: Diagrammatic representation of porous scaffold constructs (A) 
encapsulated with growth factors and its time-dependent control release (B) surface 
functionalised with growth factors either via physical adsorption or covalent 
immobilisation methods. 
 
This method avoids all issues pertaining to cell culture and expansion by allowing 
mobilisation of the patient’s own stem cells for self-reparative bone healing 
mechanisms. However, such a method relies on the ingrowth of host vasculature 
which often takes time. Other issues relating to the use of growth factors have been 
discussed earlier in Section 2.6.2. 
 
2.7.2 Prevascularisation Techniques 
To facilitate full vascularisation of the tissue-engineered graft, in vitro and in vivo 
prevascularisation methodologies have been introduced. This is done by first 
incorporating vessel structures within the graft prior to implantation at the defect site, 
with the aim of facilitating rapid anastomosis with the host vasculature and re-




growth factors  Scaffold  
Growth factor  
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2.7.2.1 In Vivo Prevascularisation 
In vivo prevascularisation involves initial implantation of the tissue-engineered graft 
within well-vascularised sites, such as the muscle, for complete vascularisation prior 
to subsequent implantation at the defect site. Figure 2-8 shows a mandibular 
replacement transplantation using a bone-muscle-flap prefabrication technique for 
the repair of a patient’s mandibular discontinuity defect. The titanium loaded with 
BMP was grown inside the latissimus muscle until adequate with a vessel pedicle 
prior to subsequent transplantation into the defected mandibular region. This 
approach allows for instantaneous reperfusion via surgical anastomosis, hence 
ensuring its therapeutic efficacy. However, it requires multiple surgeries, 




Figure 2-8: An example of an in vivo prevascularisation technique. The implant is 
grown inside the latissimus dorsi muscle, followed by subsequent transplantation in 
the mandible. Figures reproduced from Warnke et al (Warnke et al. 2004).  
 
2.7.2.2 In Vitro Prevascularisation 
Another prevascularisation method commonly referred to as the in vitro 
prevascularisation technique is one that avoids the need for an initial in vivo 
implantation. This strategy relies on the utility of endothelial cells in coculture with the 
other cell type, to generate an in vitro vascular network. It has been shown to 
augment vascularisation within the scaffold constructs which was accompanied by 
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functional anastomosis (Fuchs et al. 2007; Melero-Martin et al. 2008; Fuchs et al. 
2009; Tsigkou et al. 2010). With the preformed vessels, host vessels would only 
need to grow to the outer regions of the graft until it reaches the prevascularised 
vessels, hence, drastically shortening the time required to completely vascularise the 
tissue-engineered graft. Although this method involves the complexity of forming 
stable in vitro vasculature in the constructs and has a slower rate of anastomosis 
efficacy compared to in vivo prevascularisation, this approach avoids the need for 
multiple surgeries (Rouwkema et al. 2008).  
 
A summary comparing the advantages and disadvantages of both in vitro and in vivo 
prevascularisation approaches can be found in Table 2-5 below. 
 
Table 2-5: A summary of the advantages and disadvantages of in vitro and in vivo 
prevascularisation strategies. Adapted from Rouwkema et al (Rouwkema et al. 2008).  
In vitro Prevascularisation In Vivo Prevascularisation 
+ Does not rely on ingrowth of host   
   vasculature into entire construct 
+ No extra surgery necessary 
+ Direct perfusion after microsurgery 
+ Mature, organised vasculature 
 
-  Complex strategy, varying from   
   tissue to tissue 
-  Vessel maturation in vitro needs   
   attention 
-  Anastomosis not as fast as with in    
   vivo prevascularisation 
-  Extra implantation/surgery necessary 
-  Need of finding a proper location  
   with vascular axis for   
   prevascularisation 
-  Scaffold might be filled with fibrous   
   tissue during initial implantation 
 
Considering these vascularisation strategies, the use of a safe and efficacious off-
the-shelf vascularised BTE product that requires only one implantation surgery is 
favoured. In this project, an in vitro prevascularisation approach using a cell-based 
coculture system will be investigated. 
 
2.8 Components of Bone Tissue Engineering  
In devising a vascularised BTE graft, there are various components that need to be 
carefully considered to ensure success when combined together. These include the 
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(I)   Hydration 
(II)  Hydration and degradation 
(III) Degradation and mass loss 
(IV)  Resorption and metabolisation 
(V)   Metabolisation 
 
(A) Bioresorbable scaffold fabrication 
(B) Static cell seeding  
(C) Tissue growth in bioreactor 
(D) Tissue growth in bioreactor 
(E) Surgical transplantation 
(F) Tissue growth and remodeling 
 
converging use of osteoconductive scaffolds, osteogenic and vasculogenic cells that 




Three-dimensional (3D) scaffolds have been used in BTE to provide a local 
environment for cells, serving as temporary matrix to support/direct cellular 
growth/differentiation (Langer and Vacanti 1993) and provide mechano-induction for 
expression of growth factors and ultimately bone remodeling. Particularly for bone, 
the ideal scaffold has to be mechanically stable to temporarily support the defect 
zone while resorbing at a rate in tandem with new bone formation in the defect 
region as illustrated in Figure 2-9 (Hutmacher 2000). 
  
Figure 2-9: Graphical representation of the molecular weight loss of the 3D scaffold 
with respect to the growth and remodelling of the tissue-engineered constructs over 
time. Figure reproduced from Hutmacher et al (Hutmacher 2000). 
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In tissue remodelling, cells can recognise the architectural feature of 
microenvironment and differentiate accordingly. Therefore, it follows that the 
structural characteristics of the scaffold are important in guiding cellular distribution 
and organisation, and should be designed to mimic the trabecular bone structure 
closely. The emphasis on sufficient scaffold porosity to accommodate vascular 
infiltration, tissue ingrowth and mass transport for maintaining cell survival in thick 
grafts has also been highlighted (Figure 2-10) (Muschler et al. 2004). Most 
importantly, the biomaterial should interact with the host tissue to exert a desirable 
cellular response that aids tissue repair (Lanza et al. 2007).  
 
  
Figure 2-10: Illustration of a scaffold with a trabecular-like honeycomb structure and 
high porosity that allows for vascular infiltration, mass transport and new tissue 
formation. (Right-hand image) Scanning electron microscopy shows a honeycomb 
polycaprolactone/tri-calcium phosphate scaffold, with an average pore size within the 
range of 500µm.  
 
Fundamental scaffold design factors for consideration include type of material, its 
architecture and porosity, surface chemistry and osteoinductivity, mechanical 
strength, ease of manufacturability and clinical handling. Table 2-6 summarises the 









Table 2-6: Basic criteria and considerations when designing a scaffold for use in 
BTE applications (Hutmacher 2000; Salgado et al. 2004). 
Criteria Feature  Function 
Biocompatibility  Good integration with 
host tissue  
Do not elicit immune response 
Microarchitecture  Interconnected scaffold 
struts that complies to 
applied stresses 
To uniformly distribute stresses 
throughout scaffold 
Porosity Large surface area: 
volume, ideally with pore 
size ranging between 
200-900µm  
Allow for cell in-growth, 
neovascularisation, sufficient mass 






Affects cellular adhesion,  




To recruit and differentiate 





tuned with porosity   
To withstand loading forces in vivo; 
withstand hydrostatic pressure; allow 
for cellular in-growth and matrix 
production  
Biodegradability Biodegradable at an 
appropriate rate to match 
growth of neotissue 
To temporarily support the defect 
zone as scaffold gets replaced by 
new bone  
 
2.8.1.1 Biomaterial Selection 
The choice of an appropriate material is key in determining the properties of the 
scaffold for BTE. Current biomaterials used in BTE are limited a small selection of 
ceramics and biodegradable polymers. Ceramics have good osteoinductivity which 
makes it ideal for osteogenic cells to adhere, growth and differentiate towards an 
osteolineage (Roether et al. 2002; Lu et al. 2005). The bioactive properties of 
ceramics also allow for good bonding to native bone by forming an interfacial layer 
with surrounding tissues to prevent eventual implant expulsion. However, their main 
limitation is due to the poor processability due to their brittleness, hence making it 
difficult to process to achieve the desired porosity (Cooke 1992). Examples include 
natural origin such as coralline and synthetic hydroxyapatite (HA) or ceramics like β-
tri-calcium phosphate (β-TCP) (LeGeros 2002).  
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Biodegradable polymers are believed to be an ideal alternative. Natural polymers 
such as collagen, chitosan, hyaluronic acid have a low immunogenic potential, with a 
bioactive potential that is capable of interacting with the host tissue (Salgado et al. 
2004). Synthetic polymers are more widely used in biomedical applications as their 
biodegradation rates can be controlled as desired and they could be easily fabricated 
and shaped accordingly. Furthermore, polymers can be surface modified to attach 
appropriate chemical functional groups to achieve specific responses that help in 
directing cell growth (Gunatillake and Adhikari 2003). However, they have limited 
capabilities in achieving strong bonding and integration with bone, have weak 
mechanical properties [Elastic Modulus polymer 3GPa versus Elastic Modulus bone 
21GPa (Teoh 2004)] and some also release acidic degradation by-products in vivo, 
resulting in inflammatory responses (Bostman et al. 1990; Bergsma et al. 1995; 
Gunatillake and Adhikari 2003). Regulatory approved biodegradable and 
bioresorbable polymers include collagen, polyglycolide (PGA), polylactides (PLLA, 
PDLA) and polycaprolactone (PCL). 
 
2.8.1.2 Polycaprolactone   
PCL is a semicrystalline biodegradable polymer from the family of aliphatic 
polyesters. It has a low glass transition temperature of -60°C and low melting point 
(59-64°C). It is non-toxic and biocompatible, degrading into non-harmful by-products  
such as CO2 and water, which will not induce a deleterious inflammatory response 
unlike other polyesters. Compared to other polymers, PCL is one of the slowest in its 
degradation (>24 months) (Gunatillake and Adhikari 2003). This makes it suitable for 
long term bone implantations to provide temporary mechanical support and structural 
integrity at the defect site, while matching the rate of new bone formation and 
remodeling. However, it has poor mechanical properties with an elastic modulus of 
0.4GPa (Hutmacher 2000) as compared to 21GPa in bone (Teoh 2004). 
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2.8.1.3 Tri-calcium Phosphate 
Due to the inherent stiffness of inorganic ceramics, the incorporation of TCP [Elastic 
modulus TCP 7GPa versus Elastic modulus polymer 3GPa (Teoh 2004)] would act as a 
reinforcing material to improve the weak mechanical properties of PCL. Its 
osteoinductivity would also permit better cell growth and interaction with surrounding 
host bone (Rezwan et al. 2006; Guarino et al. 2007). The incorporation of the 
bioactive phases will increase water ingression into the polymer/ceramic interfaces, 
allowing the degradation kinetics of the polymeric scaffold to be tailored as desired 
(Hutmacher 2000; Kim et al. 2005). 
 
2.8.1.4 Proposed Scaffold – Polycaprolactone/Tri-calcium Phosphate 
Composite 
Due to the individual material limitations, the use of composite materials has been of 
increased popularity in tissue engineering approaches as it combines the desired 
properties of both materials. In this project, the use of a polymer composite scaffold 
with ceramic inclusions of TCP granules will be embedded within a polymeric matrix 
as seen in the micro-computed tomography (Micro-CT) image in Figure 2-11. 
 
Figure 2-11: Micro-computed tomography imaging of PCL/TCP composite scaffold 
showing fine TCP granules interspersed randomly within the polymer matrix 




2.8.3.1 Scaffold Design and Characteristics 
These PCL/TCP scaffolds have been used extensively in many vitro and in vivo 
experiments since the past decade. It has a unique honeycomb microarchitecture 
with a lay-down pattern of 0/60/120° and interconnected pores for promoting cellular 
bridging and ingrowth of bone tissue. At the same time, its large pores support mass 
transport and vascular infiltration into the scaffold (Figure 2-10).  
 
The efficacy of these PCL/TCP scaffolds has been demonstrated in several BTE 
investigations, exhibiting good biocompatibility and the ability to induce robust 
osteogenic differentiation and bone repair in various critical-sized defect animal 
models (Rai et al. 2007; Zhang et al. 2009; Zhang et al. 2010; Bae et al. 2011; Lim et 
al. 2011). Its unique scaffold microarchitecture also plays an important role in aiding 
in vivo vascularisation. Zhang et al (Zhang et al. 2010) and Rai et al (Rai et al. 2007) 
demonstrated the formation of extensive vasculature within the MSC or platelet-rich 
plasma-loaded PCL/TCP scaffold respectively 12 weeks post-implantation in a 
critical-sized rat femoral model. These studies demonstrate their ability of the 
scaffold construct in supporting cell adhesion, proliferation, bone formation as well as 
vessel network formation. In addition, Rai et al showed a discontinuous growth factor 
release profile from BMP-2-loaded PCL-based scaffolds in vitro (Rai et al. 2005), 
similar in fashion to the up and down regulation of various cytokines during natural 
bone repair (Ai-Aql et al. 2008), suggesting its feasibility as a drug delivery system. 
Fabricated by fused deposition modelling technique, the shape of the scaffold can be 
customised accordingly to fit the bone defect. The main features of this composite 



















• Implanted in many small and 
large animal models over long 
term without provoking a foreign 
host response 
• Showed evidence of good bony 
regeneration  
(Rai et al. 2007; Zhang 
et al. 2009; Zhang et al. 
2010; Bae et al. 2011; 
Lim et al. 2011; Yeo et 
al. 2011) 
Interconnected 
honeycomb structure and 
mechanical stiffness 
• Simulated and shown to 
uniformly distribute shear 
stresses along its filaments 
• Similar to cancellous bone 
(Singh et al. 2005) 
 
(Hutmacher et al. 2001; 
Yeo et al. 2008) 
Macro-porosity; 75% 
porous with ~ 500um pore 
size 
• Allowed for vascular infiltration 
and tissue formation 
(Rai et al. 2007; Zhang 
et al. 2010) 
Slow degradation  • Slow degradation in vitro and in 
vivo, providing temporary 
support at defect region  
(Lam et al. 2008; Yeo et 
al. 2008) 
 
Having obtained a suitable scaffold, the next step is to select reliable cells sources 
that could give rise to in vitro vessels and osteogenesis within the 3D scaffold 
construct. 
 
2.8.2 Cellular Sources 
The selection of an appropriate cell source for BTE applications is important in 
ensuring a successful outcome. Two main cell sources are considered here; one cell 
type will be selected for its osteogenic potential, and another cell type for its vessel 
forming ability. 
2.8.2.1 Osteogenic Cells 
The use of autologous fresh bone marrow aspirates is widely practiced in the clinical 
setting (Connolly 1989; Quarto et al. 2001; Hernigou et al. 2006) due to its ease of 
harvest and bone regenerative efficacy. However, its use is constrained by patient-
dependent factors that determine the quantity of osteoprogenitors in the bone 
marrow. While osteoblast remains to be the best performing osteogenic cell type, 
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they have a limited expansion in vitro with only a few cells available upon 
dissociation of tissue, hence making it challenging for applications that require large 
cell numbers (Heath 2000).  
 
The use of stem cells has presented themselves as a favourable alternative due to 
their high proliferative capability, ability to self-renew and differentiate into multiple 
tissue types upon directed induction. Their utility for bone repair has been 
demonstrated in various small and large animal models (Tseng et al. 2008). 
Embryonic Stem Cells (ESC) and induced Pluripotent Stem Cells (iPSC) are 
pluripotent stem cells that can differentiate into all cell types of the three germ layers 
and can be expanded to large numbers. However, their utility in vivo are fraught with 
concerns such as teratoma formation (Fong et al. 2010), potential immunogenic 
rejection (Drukker and Benvenisty 2004; Grinnemo et al. 2008; Zhao et al. 2011). 
Compared to other cellular sources, MSC has emerged as the most ideal cell source 
for use in BTE applications (Table 2-8) (Zhang et al. 2012). 
 
Table 2-8: Comparison of different cellular sources, including MSC for their potential 





2.8.2.2 Mesenchymal Stem Cells  
MSC are multipotent cell sources that have the capacity to differentiate into various 
cell types such as bone, cartilage, muscle, fat and other tissue types (Figure 2-12) 
(Caplan 2006). They can be readily isolated by plastic adherence from various 
sources such as the umbilical cord blood, adipose tissues, liver, amniotic fluid, with 
the bone marrow being the most well-studied source (Prockop 1997; Pittenger et al. 
1999). The ease of isolation, extensive expansion without undergoing differentiation 
(Haynesworth et al. 1992; Bruder et al. 1997) and stable phenotype in culture 
(Bruder et al. 1997; Pittenger et al. 1999) makes MSC an attractive therapeutic cell 
source for BTE. Furthermore, its low immunogenicity also suggests the potential of 
allogeneic use in therapeutic applications (Le Blanc 2003; Zhang et al. 2012). Their 
use for the treatment of various non-orthopaedic and orthopaedic diseases and 
defects in BTE have shown promising clinical results (Zhang et al. 2012). 
 
Figure 2-12: The process of mesengenesis illustrates the ability of MSC to undergo 
defined differentiate into various cellular lineages, including bone. Figure reproduced 
from Caplan et al (Caplan 2006).  
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2.8.2.3 Mesenchymal Stem Cells in Bone Tissue Engineering 
The efficacy of MSC for fracture healing has been demonstrated in various 
preclinical animal models such as rodents (Bruder et al. 1998; Meinel et al. 2006), 
dogs (Bruder et al. 1998), goats (Kruyt et al. 2004) and sheep (Bensaid et al. 2005). 
The first proof-of-principle of MSC ability in aiding bone repair and regeneration was 
demonstrated in an 8mm segmental rat femur defect. New bone formation was 
observed throughout the pores of the macroporous osteoconductive scaffold by eight 
weeks with good bony integration between the host and implant interface upon 
autogolous MSC implantation (Kadiyala et al. 1997). Other studies showed the 
efficacy of autologous bone marrow stromal cells for healing of CSD in large animal 
models (Bruder et al. 1998; Kon et al. 2000; Zhu et al. 2006), showing significant 
improvement in fracture healing and osseous integration. For example, Bruder et al 
demonstrated significant healing and defect union at a 21mm femoral defect region 
of a canine model upon implantation with MSC-loaded scaffolds, with eventual 
integration and remodelling at 16 weeks (Bruder et al. 1998). Clinically, Quarto et al 
was the first to report success in the repair of large bone defects with the use of 
autologous bone marrow stromal cells seeded onto macroporous hydroxyapatite 
scaffolds, with all three patients attaining recovery of limb function without any 
reported complications over long term monitoring (Quarto et al. 2001; Marcacci et al. 
2007).  
 
Compared to other sources of MSC, bone-marrow derived MSC (BM-MSC) are 
currently benchmarked as the next most appropriate cell source, reported to undergo 
a well-defined osteogenic differentiation pathway (Frank et al. 2002; Qi et al. 2003). 
Other cell types such as adipose, muscle, dental pulp-derived MSC are less well 
understood for their skeletal therapeutic potential (Robey 2011) as they exhibit weak 
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osteogenic differentiation in vivo (Colnot 2011) and do not support formation 
hematopoietic marrow (Robey 2011). 
 
2.8.2.4 Proposed Cell Type – Human Fetal Mesenchymal Stem Cells 
hfMSC was identified by Campagnoli et al in 2001 from first trimester fetal blood, 
liver, and bone marrow (Campagnoli et al. 2001) and found to exhibit typical MSC 
characteristics in terms of its morphology and immunophenotype and tri-lineage 
differentiation like its adult MSC (Campagnoli et al. 2001; Zhang et al. 2009). hfMSC 
was compared head-to-head to its adult counterparts, found to exhibit higher 
proliferation and osteogenic capacity, with lowered immunogenicity (O'Donoghue 
and Fisk 2004; Gotherstrom et al. 2005; Zhang et al. 2009). In terms of its 
osteogenic capacity, Guillot et al demonstrated significant reduction of fracture rates 
in osteogenesis imperfecta mice upon intrauterine transplantation of hfMSC (Guillot 
et al. 2008); Clinically, Le Blanc et al also showed engraftment and differentiation of 
hfMSC into bone after in utero transplantation in a patient with severe osteogenesis 
imperfecta, followed by consequential normal growth rates at two years of age (Le 
Blanc et al. 2005). More recently, the implantation of hfMSC-graft into a critical-sized 
rat femoral defect led to formation of an extensive vasculature network with 
functional union repair as compared to little vessel infiltration in the control group 
after 12 weeks (Figure 2-13) (Zhang et al. 2010). These studies suggest the 












hfMSC-scaffold Acellular scaffold 
 
 
Figure 2-13: hfMSC constructs showed formation of an extensive vasculature 
network with functional union repair after 12 weeks as compared to little vasculature 
in the defect region of acellular constructs. Figures reproduced from Zhang et al 
(Zhang et al. 2010).  
 
2.8.2.5 Endothelial Cell Types 
In vascularised tissue engineering, the choice of endothelial cell (EC) type used for 
prevascularisation of graft is crucial. Adult vascularisation is traditionally believed to 
occur via the process of angiogenesis rather than vasculogenesis. Angiogenesis is 
the process whereby new blood vessels are formed as mature EC sprout from pre-
existing vessel structures (D'Amore and Thompson 1987; Risau 1997), while 
vasculogenesis is the formation of new blood vessels from the differentiation of 
progenitor cells, thought to occur only in embryogenesis (Figure 2-14) (Krenning et 
al. 2009). However, recent identification of EPC have challenged this theory, 
suggesting its role in postnatal vasculogenesis for neovascularisation and 




Figure 2-14: Mechanisms of angiogenesis and vasculogenesis. (a) Sprouting 
angiogenesis from a pre-existing vessel through the secretion of matrix 
metalloproteases that degrade the vascular basement membrane, allowing 
endothelial cells to migrate and form a new vessel branch. (b) EPC forms a vascular 
plexus, deposits matrix and forms a lumen resulting in the formation of immature 
capillaries. Figure reproduced from Krenning et al (Krenning et al. 2009).  
 
2.8.2.6 Endothelial Progenitor Cells  
EPC are endothelial precursor cell types, first identified from adult peripheral blood 
(PB) by Asahara in 1997 (Asahara et al. 1997) and subsequently isolated from other 
sources such as cord blood (Murohara 2001), monocytes (Moldovan et al. 2000) and 
bone marrow (Gehling et al. 2000). EPC arise from the hemangioblasts of the 
mesodermal layer of the embryonic stem cell. Blood islands in the yolk sac of the 
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embryo grow and fuse, forming a yolk sac capillary network which differentiates into 
an arteriovenous vascular system upon the onset of blood circulation. Cells destined 
to form EPC are located at the periphery of the blood islands (Asahara and 
Kawamoto 2004; Murasawa and Asahara 2005).  
 
As a circulating cell type, EPC are immobilised from the bone marrow into the 
systemic circulation of the adult peripheral blood in response to cytokines and the 
ischemia environment during an injury. They then invade and home into sites of 
neovascularisation and then differentiate into mature EC (Murasawa and Asahara 
2005). 
 
Despite being a relatively newly identified cell type, numerous studies have since 
confirmed its vasculogenic potential. For example, exogenously administered EPC 
have been shown to augment vascularisation in diseases such as hindlimb ischemia 
(Tateishi-Yuyama et al. 2002), myocardiac infarction (Dimmeler and Zeiher 2009) 
and contributing to fracture healing via neovasculogenesis (Rozen et al. 2009; 
Atesok et al. 2010). Their success in augmenting angiogenesis and functional 
recovery has been reported in various clinical trials and animal models as reviewed 
by Krenning et al (Krenning et al. 2009). 
 
2.8.2.7 Endothelial Progenitor Cells in Fracture Healing 
Apart from promoting therapeutic neovascularisation, the contributions of EPC in 
BTE applications have also been demonstrated by several groups over the recent 
years. In a rodent tibia fracture and distraction osteogenesis model, it was suggested 
that EPC participated in neovascularisation and subsequent bone repair due to 
temporal coincidences of increased EPC mobilisation from the bone marrow, 
followed by homing at the site of injury with the fracture healing and 
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distraction/consolidation models respectively (Lee et al. 2008). Matsumoto’s group 
also demonstrated functional fracture healing via peripheral blood EPC-derived 
vasculogenesis (Matsumoto et al. 2006; Matsumoto et al. 2008; Mifune et al. 2008). 
More recently, Rozen et al demonstrated the formation of dense woven bone within 
a critical-sized defect zone in sheep tibiae 12 weeks after autologous EPC 
implantation (Rozen et al. 2009), while Atesok et al showed complete union of a rat 
femoral defect within 10 weeks (Atesok et al. 2010). These studies demonstrated the 
therapeutic efficacy of EPC in fracture repair through neovasculogenesis. 
 
2.8.2.8 Proposed Endothelial Cell Type – Umbilical Cord Blood-Endothelial 
Progenitor Cells 
Compared to their mature EC, EPC were found to be 10 fold more proliferative than 
human umbilical vein endothelial cells (HUVEC) (Murohara 2010). Furthermore, it 
was reported that transplantation of EPC demonstrated successful rescue and 
improved blood flow in hindlimb of ischaemic mice, not seen when differentiated 
microvascular EC which failed to establish limb-saving neovascularisation (Kalka et 
al. 2000). Transplantation of EPC-grafts into immunodeficient mice showed the 
formation of chimeric blood vessels interspersed with red blood cells compared to 
none observed in EC-grafts (Yoder et al. 2007). As compared to a well-defined 
circulating population of EPC (Masuda et al. 2011), mature EC have also been 
reviewed as a phenotypically and functionally heterogeneous cell type depending on 
the origin of isolation along the endothelium, which results in difficulty in 
experimental comparisons (Aird 2007), as compared to a more well-defined 
circulating population of EPC (Masuda et al. 2011). Table 2-9 compares the main 
characteristics of the mature endothelial lineages with its progenitors, with the latter 
exhibiting superiority in terms of its proliferation and vessel forming ability.  
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Table 2-9: Summary of the main characteristics of mature endothelial cells and its 
progenitor cells.  
 EPC EC 





• Peripheral blood  
• Cord blood  
• Monocytes  
• Bone marrow  
• Umbilical vein 
• Skin 
• Adipose tissue 
 
Existence Circulating in blood Lining interior surface of blood 
vessels and lymphatics 
Homogeneity • Circulating population  
• More well-defined  
 
• Origin-dependent  (Aird 
2007; Aird 2007) 
• Phenotypically and 
functionally heterogeneous 
Proliferation  10 fold higher  -                                          
(Moldovan et al. 2000) 
Vessel 
formation 
Vessel formation, perfused 
with red blood cells in vivo 
                                                
None observed  
(Yoder et al. 2007) 
 
The two most commonly explored sources of EPC are from adult PB and UCB, with  
the perinatal UCB-EPC more primitive and superior in terms of its expansion and 
differentiation capacity over its adult counterpart (Murohara 2010). Ingram et al 
reported greater proliferative capacity with at least 100 population doublings from 
UCB-EPC, maintaining high levels of telomerase activity as compared to 20-30 
population doublings in PB-EPC. UCB-EPC formed larger colonies that emerged at 
an earlier time point upon its isolation (Ingram et al. 2004). They also underwent 
faster differentiation (Kalka et al. 2000) and formed capillary-like structures faster on 
Matrigel substrate compared to PB-EPC (Ingram et al. 2004) (Table 2-10). 
 
Table 2-10: Comparison between UCB and adult PB-EPC in terms of its colony 
emergence, growth and vessel forming ability (Ingram et al. 2004). 
 Cord Blood-EPC Adult Peripheral Blood-EPC 
Colony  
formation  
• Earlier emergence  
• Larger in size and in 




• At least 100  • 20-30 
Vessel  
formation 
• Faster and more stable 
capillary-like network 
formation in vitro 
 -               
 
 56 
As UCB-EPC have been identified superior in its proliferative activity and 
vasculogenic capacity compared to their adult PB and mature EC sources, they are 




Bioreactors are primarily used to increase mass transport within tissue-engineered 
constructs to overcome the limits of oxygen diffusion distance of 100-200µm in static 
culture (Goldstein et al. 2001; Cartmell et al. 2003). Dynamic cultures add convection 
forces which help to improve nutrient and oxygen supply to the cells, as well as 
assist in the removal of waste materials. They were also found to improve cell 
viability and cellularity within the tissue-engineered grafts (Wendt et al. 2003). For 
example, Zhang et al demonstrated improved cellular viability in dynamically-cultured 
hfMSC-grafts as compared to massive necrosis within the core of the static-grafts 
(Zhang et al. 2009). Bioreactor cultures also ensure homogenous cellular distribution 
(Wendt et al. 2003; Wendt et al. 2005) and enhanced osteogenic differentiation 
(Bancroft et al. 2002; Datta et al. 2006). The mechanical cues involved trigger onset 
of several signalling pathways which has been shown to positively influence the 
osteogenic properties of the graft (McCoy and O'Brien 2010) as well as fundamental 
to endothelial differentiation and vascular development (Tzima et al. 2005).  
 
For example, fluid shear stress has been shown to promote osteogenic 
differentiation of MSC (Sikavitsas et al. 2003; Datta et al. 2006; Holtorf et al. 2006; 
Zhang et al. 2009). Sikavitsas et al showed increased mineral deposition in the 
scaffold meshes with a more homogenous ECM as compared to a thin mineralised 
ECM obtained in static culture (Sikavitsas et al. 2003). Meinel et al also 
demonstrated more robust bone formation with accelerated repair of calvarial critical-
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sized mice defect upon implantation of human MSC-scaffolds cultured in 5 weeks of 
bioreactor culture in bone inductive media compared to its non-treated hfMSC-
scaffolds and empty scaffolds (Meinel et al. 2005).  
 
In terms of endothelial differentiation, EPC cultured under dynamic culture showed 
enhanced vasculogenic potential after Matrigel-induced differentiation (Yamamoto et 
al. 2003). A similar phenomenon has been described in murine embyonic stem cell-
derived endothelial cells, which displays heightened endothelial cell characteristics 
and maturation under dynamic culture conditions but not in static culture (McCloskey 
et al. 2006). 
 
As osteoprogenitors and endothelial cells are mechano-sensitive cell types, it is 
hypothesised that the exertion of biomechanical stimulation on the coculture system 
is likely to contribute towards the maturation of vessel and bone formation within the 
graft construct. 
 
2.8.3.1 Proposed Bioreactor – Perfusion Biaxial Bioreactor 
Some commonly used commercial bioreactors for BTE applications include spinner 
flasks, rotating wall vessels and perfusion bioreactors with their associated 
advantages and disadvantages as described in Table 2-11 (Rauh et al. 2011). 
Notably, these bioreactors are mostly uniaxial in rotation, possibly resulting in a non-
homogenous media flow and nutrient exchange especially within the internal zones 







Table 2-11: Comparison of the advantages and disadvantages of the various modes 
of commonly used bioreactors. Figures reproduced from Hutmacher and Singh 
(Hutmacher and Singh 2008). 










• Media stirring ↑ mass 
transfer via 
convective transport 
• ↑ osteogenicity  
• Generates turbulent eddies 
detrimental to cell 
development  
• No direct perfusion of media 















low shear stresses 
with high mass 
transfer 
• Constructs in a state of 
free-fall in media; frequent 
collision with bioreactor wall 
• No direct perfusion of media 
into scaffold 
















• Media flows directly 
through pores of 
constructs, 
enhancing mass 
transfer internally  
• ↑ osteogenicity 
• Customised cartridge to fit 
constructs 
• Cell “wash-out” due to 
continuous perfusion 
 
In mimicking the multiaxial forces experienced by the bone during daily activities, a 
biaxial bioreactor was designed (US Patent 7,604,987 B2). Briefly, the biaxial 
bioreactor consists of a culture vessel capable of rotating in two perpendicular axes 
simultaneously. Media is perfused continuously throughout the chamber from the 
media reservoir, where cellular-scaffold constructs are secured to the pins during 
rotation (Figure 2-15) (Hutmacher and Singh 2008). 
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Figure 2-15: The perfusion biaxial bioreactor has two rotational axes (indicated by 
blue block arrows), with scaffolds pinned and fixed in place while the bioreactor 
rotates. Figures reproduced from Zhang et al (Zhang et al. 2009).  
 
Computational modelling analysis of fluid velocities and shear stresses 
demonstrated increased fluid velocity and fluid transport within scaffold constructs 
when rotated in a biaxial manner (Singh et al. 2005). This was then experimentally 
verified and found to significantly enhance cellular viability within hfMSC-grafts upon 
dynamic culture, as compared to massive necrosis observed in a static-cultured one 
after 28 days (Zhang et al. 2009). Furthermore, when used in conjunction with the 
proposed macroporous PCL/TCP scaffold, shear stresses were found exerted 
uniformly along the scaffold filaments upon the biaxial rotational action of the 
bioreactor (Singh et al. 2005). 
 
More recently, a head-to-head comparison of commercially available bioreactors 
operated at their optimal settings (spinner flasks, perfusion and rotating wall vessel 
bioreactors) revealed the superiority of the biaxial bioreactor in ensuring an even 
distribution of seeded hfMSC with the scaffolds, higher proliferation rates, and earlier 
and more robust osteogenic differentiation (Zhang et al. 2009). This suggests 
improved performance of the biaxial bioreactor over other bioreactor systems for the 
generation of bone grafts in BTE. 
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In this project, the biaxial bioreactor will be used in conjunction with the coculture of 
stem cells and scaffolds. The aim is to generate highly vascularised and osteogenic 
bone grafts that are highly confluent and viable, with an even distribution of cells 
throughout the graft prior to implantation. 
 
2.8.4 Hypoxia in the Natural Physiology 
Adult tissues experience low oxygen tensions upon inhalation of atmospheric air, 
which progressively decreases in partial pressure as oxygen travels through the 
nasal pathway first into the lungs, via the blood, then to the various tissues 
(Mohyeldin et al. 2010). Early experiments measured low oxygen levels in tissues of 
developing embryos (Mitchell and Yochim 1968), and hypoxia was found to influence 
both embryonic and adult stem biology in recent in vitro studies (Panchision 2009; 
Silvan et al. 2009; Eliasson and Jonsson 2010). Low oxygen tensions have also 
been identified in the various stem cell niches (MSC, neural and hematopoietic 
niches) in the human body (Mohyeldin et al. 2010). In the bone marrow, progenitor 
cells such as MSC and EPC reside at a low oxygen tension of approximately 2-8%. 
Hence, the study of oxygen tension for cell culture is physiologically relevant and is 
believed to be a critical parameter for the maintenance of stem cell phenotype and 
stem cell fate. 
 
2.8.4.1 Hypoxia and Mesenchymal Stem Cells 
There has been an increase in interest investigating the effects of hypoxic culture on 
MSC growth, proliferation and differentiation in the realm of tissue engineering. Most 
studies demonstrated increased proliferative rates on monolayer and 3D substrates 
under hypoxic culture. In terms of its osteogenic capacity, there have been 
contradictory reports on the effects of hypoxia on the osteogenic differentiation of 
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MSC (Das et al. 2010), although likely attributed to the lack of standardisation of 
various parameters (cell source, duration of exposure, exact O2) between studies. 
More experiments need to be performed to understand the effects of hypoxia 
preconditioning on MSC differentiation for enhancing fracture repair response upon 
cell transplantation. 
 
2.8.4.2 Hypoxia and Bone Repair 
The role of hypoxia in triggering angiogenesis has been described earlier in Section 
2.5.2. In terms of its contributions towards bone formation, hypoxia has also been 
found to exert profound effects in accelerating bone repair. HIF-1α and its activated 
pathway has been demonstrated to aid in skeletal development, stimulating 
osteoprogenitor differentiation and promoting robust bone formation and remodelling, 
which was coupled by the action of angiogenic mechanisms (Wan et al. 2010). 
Experimentally, Wang et al showed robust bone formation accompanied by VEGF 
upregulation upon constitutive activation of HIF-1α pathway in osteoblasts, while the 
inhibition of HIF-1α led to the formation of narrow and less vascularised bones 
(Wang et al. 2007). A similar improvement in vascularity and bone formation finding 
was noted in distraction osteogenesis mice upon Von Hippel-Lindau deletion with 
constitutive HIF-1α activation compared to mice lacking HIF-1α (Komatsu and 
Hadjiargyrou 2004; Wan et al. 2008). Also, Zou et al induced the overexpression of 
HIF-1α through lentiviral mediated gene delivery in bone marrow-derived MSC, 
leading to significantly improve the vessel forming and osteogenic potential for the 
repair of a CSD calvarial rat defect as compared to its LacZ control (Zou et al. 2011). 
These studies reiterate the interdependent relationship between vascularisation and 
its ability to aid in bone formation as discussed earlier (Section 1.5.1). 
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2.9 Coculture Systems 
2.9.1 Trends in Coculture Systems 
In the area of coculture systems in tissue engineering, there has been a steep 
increase in the number of publications since the past two decades (259 publications), 
with a significant proportion dedicated to BTE (85 publications). The top 10 
institutions and leading experts in this area are as listed in Table 2-12 below (Web of 
Science, 2012). 
 
Table 2-12: (A-B) Citation analysis on the utility of cocultures in tissue engineering 
and bone tissue engineering respectively, as well as the leading institutions and 
experts. 
A. Top 10 (Coculture and Tissue Engineering) 
 





1 Harvard  Univ 9 Okano T 8 
2 Tokyo Womens Med Univ 8 Finkenzeller G 7 
3 Univ Freiburg 8 Stark GB 7 
4 MIT 7 Yamato M 7 
5 Univ Toronto 7 Kirkpatrick CJ 6 
6 Kyushu Univ 6 Ito A 5 
7 Tufts Univ 6 Kaplan DL 5 
8 Univ Michigan 6 Wenger A 5 
9 Duke Univ 5 Zhang Y 5 




B. Top 10 (Coculture and BTE) 
 




1 Univ Freiburg 6 Finkenzeller G 5 
2 Natl Univ Singapore 4 Kirkpatrick CJ 5 
3 Nanjing Med Univ 3 Stark GB 5 
4 Sichuan Univ 3 Wenger A 4 
5 Univ Med Ctr Utrecht 3 Fuchs S 3 
6 Univ Minho 3 Reis RL 3 
7 Capital Med Univ 2 Santos MI 3 
8 Hokkaido Univ 2 Toh SL 3 
9 Inserm 2 Unger RE 3 
10 Johannes Gutenberg 
Univ Mainz 
2 Zhang Y 3 
 
 
2.9.2 Cocultures in Vascularised Bone Tissue Engineering 
Leveraging on the osteogenic and vasculogenic properties of osteoblast-like and 
endothelial monocultures respectively, many groups have utilised a coculture system 
on the premise that this strategy will generate prevascular networks within BTE 
grafts towards aiding bone repair (Fuchs et al. 2007; Melero-Martin et al. 2008; 
Fuchs et al. 2009; Usami et al. 2009; Seebach et al. 2010; Tsigkou et al. 2010). Most 
reported studies have showed phenomenal observations of increased 
vascularisation upon the addition of endothelial lineages in coculture, with some 
showing evidence of integration and chimeric vessel formation in vivo (Table 2-13). 
Fuchs et al demonstrated greater potential for vascular network formation, with 
highly organised microvessel-like structure formation when osteoblastic cells were 
cocultured with PB-EPC (Fuchs et al. 2007). Tsigkou et al  demonstrated endothelial 
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tubular networks within the first week, followed by a stabilised mature vascular 
network within a mineralising bone graft by Week 4 upon coimplantation of 
undifferentiated MSC and HUVEC subcutaneously in mice  (Tsigkou et al. 2010). 
 
Although many groups have also shown an increase in osteogenic differentiation 
upon coculture, few have demonstrated strong evidence for bone healing and 
regeneration in vivo. Usami et al showed a 1.6 fold increase in capillary density and 
1.3 fold increase in bone formation compared to the use of MSC alone, suggesting 
the necessity of vasculature formation in aiding bone regeneration (Usami et al. 
2009). Orthotopic implantation of the EPC/MSC construct led to earlier 
vascularisation and significantly more bone formation in a rat femoral CSD model, 
with higher ultimate loading than the MSC alone group (Henrich et al. 2009; Seebach 
et al. 2010). The coculture systems and their in vivo performance in promoting 
vascularisation and/or bone formation in various animal models are summarised in 
Table 2-13. 
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Table 2-13: Summary of various animal models used for implantation of coculture systems in vascularised BTE. * Denotes an orthotopic 




like cell type 
Cell 
origin 
Animal model Implantation result Reference 
BM-MSC 
 
Human 4.3mm calvarial 
critical sized 
defect in mice * 
Coimplantation led to higher human CD31+ neovessels formation but without 
increase in bone formation compared to MSC-alone 
(Koob et al. 
2011) 
BM-MSC Human Subcutaneous in 
mice  
HUVEC-vascular networks infiltrated the scaffold after 4-7 days after 
implantation, with anastomosis after 11 days; Networks were mature at 4 
weeks, with initial mineralisation. Human-derived vessels persisted at 5 months 
but majority remodeled with host vasculature 
(Tsigkou et 
al. 2010) 
BM-MSC  Human 0.9mm diameter 
femoral defect in 
mice * 
In vivo mineralisation was observed inside and around cellular-microspheres, 






Human Subcutaneous in 
mice  
Vessel networks with lumens were formed but with limited anastomosis 
confined to implant periphery 
(Rouwkema 
et al. 2006) 
 
Primary OB Human Subcutaneous in 
mice 
Coimplantation led to formation of human HDMEC-vessels that integrated with 
host vasculature and were perfused, inducing murine vasculature into the 
implants as compared to none in HDMEC-alone 
(Unger et al. 
2010) 
HDMEC 
BM-MSC Human Subcutaneous in 
mice 
Coimplantation showed greater human-derived vessels on Week 8, with more 
bone tissue formation compared to MSC-alone, found to be mediated by BMP-





Human 5mm femoral 
defect in rat * 
EPC-implanted groups showed early vascularisation, but coculture group 
showed significantly more bony bridging with increased ultimate load 
compared to other groups 
(Seebach et 
al. 2010) 
Primary OB Human  Subcutaneous in 
mice  
Coimplantation increased neovascularisation, with the formation of perfused 
human EPC-vessels that anastomosed with host vasculature compared to 
EPC alone 
(Fuchs et al. 
2009) 
BM-MSC  Human 5mm femoral 
defect in rat * 
EPC-loaded implants improved neovascularisation; a trend towards increased 




BM-MSC  Canine Subcutaneous in 
mice  
Coimplantation increased neovascularisation and bone formation compared to 
MSC-alone 
(Usami et al. 
2009) 




 mice number of vessels were found decreasing in descending order when 
cocultured with EPC, HUVEC, MVEC respectively, however with greater 
degree of organisation  
et al. 2009) 
BM-EPC BM-MSC 
 
Goat Subcutaneous in 
goat 
Cellular-implants led to higher bone lining scaffold compared to acellular-






BM-MSC  Human Subcutaneous in 
mice 
Coimplantation led to greater number of vascular structures with engraftment 
into host vascular endothelium and increased ectopic mineralisation as 
compared to MSC-alone; Angiogenesis was further increased upon VEGF 
stimulation 
(Moioli et al. 
2008) 
Legend: BM-EPC – Bone marrow derived EPC; OB – osteoblast; HDMEC – human dermal microvascular EC; HSC- Haematopoietic stem cell 
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2.9.3 Considerations for Coculture Systems 
Keeping in mind an appropriate choice of BTE components including cell types, 
scaffolds, bioreactor and microenvironmental oxygen tensions (Section 2.9), there 
are other culture parameters for consideration in ensuring a successful outcome of 
the coculture system. 
 
2.9.3.1 Choice of Media 
One consideration factor involves the choice of culture media for the maintenance of 
cellular viability of both cell types as well as for tissue development. Suitable optimal 
conditions for inducing both vessel network and bone formation, without adverse 
influence on cellular differentiation of the other cell type needs to be identified. In 
addition, the state of cellular differentiation of the graft prior to implantation is crucial 
in determining its in vivo performance. It was reported that pre-differentiation of 
osteoblast-like cells in bone inductive media prior to implantation accelerates the rate 
of bone formation in vivo compared to undifferentiated MSC (Breitbart et al. 1998; 
Bruder and Fox 1999). In addition, a recent investigation by Schantz and coworkers 
compared the efficacy of tissue formation of undifferentiated MSC and osteoblasts-
loaded scaffolds in a rabbit calvarial defect. Results revealed the importance of 
directing MSC towards a specific lineage prior to implantation which its cell fate will 
otherwise be likely determined by its immediate host environment (Schantz et al. 
2012). However, it is imperative to keep in mind that the differentiated state of MSC 
might interfere with its role as a pericyte for enwrapping and stabilising the pre-
forming vascular network. 
 
Most groups have investigated their coculture systems in one media type often 
without justification for the choice of media used, while some have utilised a 
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combination of cell culture media optimal for the different cell types. Table 2-14 
shows a compilation of the various media types used in current coculture systems for 
BTE. However, the heterogeneity of the experimental parameters in these studies 
makes comparison between coculture systems challenging. In a recent head-to-head 
study of various media types (bone media with/without endothelial supplements, 
endothelial-based media with/without osteoinductive supplements) for MSC/EPC 
coculture, a general trend towards enhanced vessel formation or more robust 
mineralisation was noted when endothelial growth media (EGM) and bone media 
(BM) were used respectively. Kolbe et al showed increased microvessel formation 
efficiency when cultured in EGM as compared to BM with or without growth factor 
supplements; while the use of BM was found to demonstrate higher osteogenic 
differentiation capacity of MSC as compared to the other media types (Kolbe et al. 
2011). Few groups have utilised bone inductive media for the cocultures, lest poor 
endothelial survival. It was also verified that bone inductive media was the most 
effective towards inducing osteogenic differentiation of MSC, while there was a lack 
of osteogenic modulation in EGM-variants (Liu et al. 2012). While growth factors 
supplemented in EGM may effectively promote endothelial differentiation, care must 
be taken into consideration in ensuring no inhibition of osteogenic differentiation.  
 
Hence, the choice of media and its various soluble components such as angiogenic 
growth factors and bone inductive components plays an important role in determining 
cellular fate and differentiation, and needs to be carefully considered in this project. 
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Table 2-14:  Maintenance of coculture systems in BTE, including media used, 
coculture ratios and the seeding methodology, with coculture in direct contact unless 
otherwise stated.  
Coculture Media Cell types Reference 
MSC, EC  (Villars et al. 2000) 
MSC, HUVEC (Villars et al. 2002) 
OB, HUVEC (Guillotin et al. 2008) 
OB, HUVEC (Hofmann et al. 2008) 
MSC, HUVEC  (Grellier et al. 2009) 
IMDM-based media 
MSC, EPC (Aguirre et al. 2010) 
MSC, EPC (Henrich et al. 2009) MesenCult-based 
media MSC, EPC (Seebach et al. 2010) 
MG-63 or OB, HDMEC (Unger et al. 2007) 
MSC, EPC (Fuchs et al. 2009) 
OB, EPC (Fuchs et al. 2009) 
MSC, EC (Xue et al. 2009) 
EGM-based media 
OB, EPC (Dohle et al. 2010) 
Bone media MSC, EPC in BM  (Liu et al. 2012) 
MSC, EC in EGM2: DMEM10 (1:1) (Kaigler et al. 2005) 
MSC, HUVEC in EBM2, BM, EBM2:BM 
(1:1) 
(Rouwkema et al. 2006) 
MG-63 or OB, EPC in EGM-2 with or 
without osteogenic supplements 
(Fuchs et al. 2007) 
MSC predifferentiated in BM, EPC in 
EGM2 individually cultured and 
implanted  
(Usami et al. 2009) 
MSC, EPC in αMEM15:EGM20 (1:1) (Geuze et al. 2009) 
MSC predifferentiated in BM, then in 
coculture with EC in EGM2 
(Tsigkou et al. 2010) 
MSC, HUVEC in IMDM, Medium 199 
(M199), DMEM and M199:DMEM (1:1) 
(Bidarra et al. 2011) 
MSCs predifferentiated in BM, then 
cocultured with HUVEC grown in EBM 
with VEGF-A and bFGF 
(Koob et al. 2011) 
Separately cultured 
or in mixed media 
MSC, EPC in EBM2, EGM2 with or 
without osteogenic supplements, BM 
with or without endothelial supplements 
(Kolbe et al. 2011) 
 
Legend: OB – osteoblast; MG-63 – osteosarcoma cell line; HDMEC – human dermal 
microvascular EC; IMDM - Iscove's Modified Dulbecco's Media; DMEM - Dulbecco's 
Modified Eagle's Medium; αMEM - Alpha Minimum Essential Medium; Figure 
following media type denotes % fetal bovine serum. 
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2.9.3.2 Seeding Methodology 
There are several methodologies used for seeding cells onto 3D scaffold constructs, 
although the optimal methodology has yet to be defined. Some consideration factors 
include the manner in which cells are cultured prior to implantation, whether cells 
should be combined or cultured separately in their optimal culture media, the need 
for a dynamic culture system and the duration of biomechanical stimulation before 
implantation. Other considerations relate to cellular distribution of the coculture in the 
graft, and the seeding ratios that should be used to allow for efficient cellular 
interactions and cross-talk. Table 2-15 summarises the possible advantages and 
disadvantages associated with the various seeding methodologies which could 
significantly impact on the outcome of this coculture strategy. 
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Table 2-15: Advantages and disadvantages of various seeding methodologies of cocultures in vascularised BTE. 
Seeding methodology  Advantages Disadvantages Reference 
Combining coculture directly • Logistically simple  
• Even cellular mix distributed 
within the construct 
• Need to ensure cell survival in the same media type 
prior to seeding without alteration to monoculture 
cellular properties 
1. (Unger et al. 2007) 
2. (Unger et al. 2010) 
3. (Hofmann et al. 2008) 
4. (Fuchs et al. 2007) 
5. (Henrich et al. 2009) 
6. (Seebach et al. 2010) 
7. (Villars et al. 2002)  
8. (Guillotin et al. 2008) 
9. (Geuze et al. 2009) 
10. (Bidarra et al. 2011) 
11. (Melero-Martin et al. 
2008)  
12. (Fuchs et al. 2009) 
13. (Rouwkema et al. 2009) 
14. (Koob et al. 2011) 
15. (Liu et al. 2012) 
2-step protocol  
 
(A) Seeding OB first, then 
EPC on same scaffold 
1. (Dohle et al. 2010) 
2. (Fuchs et al. 2009) 
3. (Tsigkou et al. 2010) 
(B) Seeding OB and EPC on 
different scaffolds which can 
be then combined together. 
• Allow monocultures to 
develop optimally in their 
respective growth media, 
maintaining individual 
phenotypic characteristics 
• Uneven distribution of cells, where EPC are mostly 
attached to scaffold surfaces rather than within the 
scaffold core 
• Prevascularises the EPC zones of the scaffold only, 
and might be difficult for vessels to infiltrate if 
osteogenic graft is highly confluent  
• Minimal EPC/MSC interactions between coculture 
1. (Usami et al. 2009)  
Coculture followed by 
dynamic stimulation   
• Improve metabolic and 
osteogenic activity 
• Assist in maturation of graft 
• Logistically more challenging 1. (Grellier et al. 2009)  
 
 72 
In summation, few groups have investigated coculture systems in conjunction with 
bioreactor technologies (Grellier et al. 2009) or under a hypoxic culture environment 
(Gawlitta et al. 2012). So far, Grellier and coworkers are the only team to have 
reported the dynamic culture for cell-encapsulated alginate microspheres prior to 
subsequent assays comparing its cocultures of human osteoprogenitors and HUVEC 
to its monocultures. There has been yet to be any reports on the influence of 
dynamic culture on osteoblast-endothelial cell cocultures for vascularised BTE 
towards aiding vascular and bone development.  
 
While hypoxia is highly relevant in the natural physiology of the vascularised bone, 
few have investigated the effects of low oxygen tensions on a coculture system. A 
recent study investigated the effect of hypoxic cultures on EPC/MSC on the 
hypothesis that a hypoxic environment will contribute to prevascularisation. Results 
however, showed an impediment of vaculogenesis upon hypoxia stimulation as 
compared to their normoxic cultures which supported the formation of 
prevascularised structures (Gawlitta et al. 2012). More studies need to be done to be 
done to verify the importance of a hypoxic stimulus for the purpose of 
prevascularising tissue-engineered coculture constructs and facilitating bone 

















Chapter 3 – Materials and Methods 
We are all faced with a series of great opportunities  
brilliantly disguised as impossible situations ~ Charles R. Swindoll 
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Chapter 3 - Materials and Methods  
3.1 Samples, Animals and Ethics 
Human tissue collection for research purposes was approved by the Domain Specific 
Review Board of National University Hospital Systems (DSRB-D-06-154), in 
compliance with international guidelines regarding the use of fetal tissue for research 
as previously described (Zhang et al. 2010). In all cases, patients gave separate 
written consent for the use of the collected tissue. Fetal femurs were collected for 
isolation of hfMSC after clinically-indicated termination of pregnancy. In this study, a 
sample derived from a 17+3 weeks+days gestation was used. Human UCB samples 
from newborns were collected from normal term deliveries.  
 
Male non-obese diabetic severe combined immunodeficient (NOD SCID) mice (6-8 
weeks old) were acquired from Animal Resources Centre (Canning Vale, Western 
Australia). All procedures were approved by the Institutional Animal Care and Use 
Committee at The National University of Singapore, and procedures performed in the 
Association for Assessment and Accreditation of Laboratory Animal Care 
International (AAALAC) accredited animal facilities. 
 
3.2 Cells 
3.2.1 Cell Isolation, Culture and Characterisation   
3.2.1.1 Human Fetal Bone Marrow Derived Mesenchymal Stem Cells 
hfMSC were isolated from bone marrow as previously described (Zhang et al. 2009). 
Briefly, single-cell suspensions were prepared by flushing the bone marrow cells 
from femurs using a 22-gauge needle, passed through a 70µm cell strainer (BD 
Falcon, USA) and plated on 10 cm diameter plates (NUNC, USA) at 106 cells/ml. 
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Adherent spindle-shaped cells were recovered from the primary culture after 4 to 7 
days. Non-adherent cells were removed with initial media changes every 2-3 days. 
At subconfluence, they were trypsinised and replated at 104 cells/ cm2. MSCs were 
cultured in Dulbecco modified Eagle media (DMEM)-Glutamax (GIBCO, USA) 
supplemented with 10% fetal bovine serum (FBS), 50U/mL penicillin and 
streptomycin (GIBCO, USA), thereafter referred to as D10 media. hfMSC were 
screened using flow cytometry for MSC markers such as CD73, CD90, CD105; 
hematopoietic and endothelial markers such as CD14, CD34, CD45 respectively 
using a human MSC phenotyping kit. Their tri-lineage differentiation capacity was 
also confirmed upon directing the cells towards adipogenic, chondrogenic and 
osteogenic lineage in the respective media. Cells from passage 2-4 were used and 
characterised as previously described (Zhang et al. 2010). 
 
3.2.1.2 Human Umbilical Cord Blood Derived Endothelial Progenitor Cells  
UCB-EPC were obtained as previously described (Yoder et al. 2007). Briefly, blood 
was diluted and overlaid onto Ficoll-Paque PLUS (Amersham, Piscataway, NJ). 
Mononuclear cells (MNC) from the buffy coat retrieved from UCB by low density 
centrifugation were resuspended in EGM (Cambrex, USA) supplemented with 10% 
FBS, thereafter referred to as EGM10, and then plated onto 10 cm diameter tissue 
culture dishes coated with Type I rat tail collagen (BD Biosciences, Bedford, MA) at 
37°C, 5% CO2 in a humidified incubator. Culture media was changed every 3 days 
subsequently. Typical cobblestone colonies appeared after two weeks, and were 
subcultured at subconfluence. Immunocytochemistry was used to screen EPC for DiI 
complex acetylated low density lipoprotein (DiI acLDL) (Dako, Denmark), CD31 
(Millipore, USA), vWF (Millipore, USA) and VE Cadherin (Enzo Life Sciences, USA). 
 
 76 
3.2.2 Lentiviral-Transduction of hfMSC and EPC 
The lentiviral vectors were produced as described previously (Chan et al. 2005). 
Briefly, the transfer plasmids (PGK-H2BmCherry / pHIV-dTomato and 
pRRLSIN.cPPT.PGK-GFP.WPRE) were cotransfected with pMD2.G and 
pCMV.∆R8.74 into HEK293T cells. The supernatant was collected at 48 and 72 
hours following transfection and concentrated by two rounds of ultracentrifugation at 
50,000 g for 2 hours and the final pellet was dissolved in a small volume of 1% BSA 
in PBS (1/100 of starting volume). The number of transducing units (TUs) of the 
vectors was determined by infecting 100,000 293T cells using serial dilution of the 
vector. The dilution resulting in <30% green fluorescent protein (GFP) or red 
fluorescent protein (RFP)-positive cells was used to calculate the number of TUs per 
ml. For transduction, cells were seeded at 0.5x104 cells/cm2 in T-25 flasks, and 
exposed to lentivirus with 4 mg/mL polybrene at multiplicity of infection of 5. GFP 
labelled EPC and nuclear-mCherry labelled hfMSC at >90% transduction efficiencies 
were used in the experiments. 
 
3.3 Flow Cytometry 
MSC were trypsinised, spinned down and enumerated. 1X106 cells were then 
suspended in buffer (PBS supplemented with 20% Goat Serum, 0.5% Bovine Serum 
Album, 2mM EDTA) and incubated with the MSC Phenotyping Cocktail (MACS, 
Germany) for 30 minutes in the dark at 4°C. Cells were washed before resuspending 
the cell pellet in buffer for analysis by flow cytometry. Flow cytometry was first carried 
out on an unstained sample, where the population of cells have been gated to 
exclude any debris. The gate was then applied to both the sample group stained with 
the marker of interest and its histogram was overlaid with that of the unstained group. 
The percentage of positively-stained cells were measured.  
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3.4 Multilineage Differentiation 
3.4.1 Adipogenic Differentiation 
To induce adipogenic differentiation, MSC were plated at 2 X 104/cm2 and cultured in 
adipogenic differentiation medium (D10 medium supplemented with 5µg/ml Insulin, 
10-6M Dexamethasone and 0.6 X 10-4M Indomethacin) (Sigma Aldrich, USA) for up 
to 21 days with change of medium three times per week. The existence of lipid 
vacuoles was confirmed by Oil-Red O staining. 
3.4.2 Chondrogenic Differentiation 
To induce chondrogenic differentiation, MSC were pelleted and cultured in 
chondrogenic differentiation medium (DMEM medium supplemented with 0.1µM 
Dexamethasone, 0.17mM ascorbic acid, 1.0mM Sodium Pyruvate, 0.35mM L-Proline, 
1% ITS (BD Pharmingen, USA), 1.25 mg/ml BSA, 5.33µg/ml Linoleic acid and 
0.01µg/ml TGF-beta) (Sigma Aldrich, USA) for up to 28 days with change of medium 
three times per week. The spheroid cell masses were fixed, embedded and 
microtome cut before Alcian Blue staining.  
3.4.3 Osteogenic Differentiation 
To induce osteogenic differentiation, MSC were plated at 2 X 104/cm2 and cultured in 
osteogenic differentiation medium (D10 medium supplemented with 10mM β-
glycerophosphate, 10-8M Dexamethasone and 0.2mM Ascorbic Acid) (Sigma Aldrich, 
USA) for up to 14 days, with change of medium three times per week. Evidence for 
extracellular accumulation of calcium was assayed by von Kossa staining. 
 
3.5 Preparation of EPC Conditioned Media  
To obtain EPC conditioned media (EPCCM), EPC were cultured in EGM10 until 
confluence, washed thrice with PBS prior to the addition of BM. Media were collected 
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after 72 hours, centrifuged, filtered through a 0.22µm filter and further diluted in 
ratios of 1:1 and 1:10 with BM, thereafter referred to as EPCCM (1:1) and EPCCM (1:10) 
respectively. 
 
3.6 Osteogenic Assays  
3.6.1 Calcium Assay 
Calcium deposition was assayed as previously described (Zhang et al. 2010). Briefly, 
each sample well (n=3) was incubated with 0.5N acetic acid overnight to dissolve 
calcium. A colorimetric calcium assay kit (BioAssay Systems, USA) was used to 
quantify calcium content spectrophotometrically at 612 nm according to 
manufacturer’s instruction.  
3.6.2 Alkaline Phosphatase Assay 
Alkaline phosphatase (ALP) was assayed as previously described (Zhang et al. 
2010). Briefly, samples (n=3) were gently rinsed twice with PBS, and incubated in 
1mg/ml of Collagenase Type 1 (Sigma Aldrich, USA) dissolved in 0.1% Trypsin 
(Invitrogen, USA) solution and incubated at 37 °C for 2 hours to digest the 
extracellular matrix completely. After three cycles of freeze-thaw, the cell lysate 
solution was assayed for ALP activity using SensoLyte™ pNPP Alkaline 
Phosphatase Assay Kit (AnaSpec, USA) following the manufacturer’s instruction.  
3.6.3 Von Kossa Staining 
Von Kossa staining was performed as previously described (Zhang et al. 2010). 
Briefly, samples were gently rinsed twice with PBS then fixed with 10% formalin for 1 
hour, followed by 2 washes with distilled water and stained with freshly made 2% 
Silver nitrate (Sigma Aldrich, USA) in distilled water (w/v) for 10 minutes in the dark 
and expose to sunlight for 30 minutes.  
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3.7 Antibody Array and Microarray Scanning 
Semi-quantitative G series antibody arrays 6, 7, 8 (Human Cytokine Antibody Array 
(RayBiotech, USA) were used to detect 174 cytokines as per manufacturer's 
instructions. Briefly, after blocking the arrays with blocking buffer for 30 minutes, they 
were incubated with either EPCCM or BM for 2 hours at room temperature. Samples 
were decanted from each well and washed 3 times with Wash Buffer, incubated with 
Biotin-conjugated antibodies, and followed by Fluorescent dye-conjugated 
streptavidin for 2 hours each. Thereafter, arrays were washed, centrifuged and 
allowed to dry before scanning at an excitation frequency of 532nm (Axon Genepix 
4000B, USA). Background signals obtained from the negative control, bovine serum 
albumin (BSA) were subsequently subtracted from median values and sample 
averages were normalised against the positive control, biotinylated protein as 
supplied by the manufacturer. Signals from EPCCM were then subtracted from BM 
values and analysed. 
 
3.8 Microarray Analysis of Gene Expression 
Two microarray analyses were performed. In the first, total ribonucleic acid (RNA)  
was extracted from UCB-EPC grown to subconfluence in biological triplicates, using 
the RNeasy kit (Qiagen, Valencia, CA) as per the manufacturer’s protocol. Ten 
micrograms total RNA were used to generate labeled cRNA and hybridised to 
Human Genome U133 Plus 2.0 arrays (Affymetrix, Santa Clara, CA). Data files were 
imported into GeneSpring GX 11 (Agilent Technologies, Palo Alto, CA). In the 
second microarray analysis, data files of UCB-EPC (gse508535) and adult peripheral 
blood-derived EPC (PB-EPC) (gsm508539-41) samples from Gene Expression 
Omnibus Series gse20283 (www.ncbi.nlm.nih.gov/geo) as published by Medina and 
colleagues (Medina et al. 2010) were imported into GeneSpring GX 11. Data files 
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from both microarray studies were subjected to normalisation, summarisation and 
Gene Ontology (GO) analysis with GeneSpring GX 11. Probe sets related to 
osteogenesis were identified by the related GO terms (GP:0001503 and children) 
(Ashburner et al. 2000). In the analysis of EPC transcriptome, selected probe sets 
were sorted in descending order of the mean expression of triplicate samples, and 
color-coded with the highest red, median (4.59) yellow and lowest blue. Further 
details are described in supporting information data.   
 
3.9 Quantitative Polymerase Chain Reaction Analysis 
mRNA derived from UCB-EPC (n=1) and adult PB-EPC samples (n=2) were 
obtained from Belfast, UK. Extracted total RNA of EPC derived from UCB and 
human adult peripheral blood were supplied by Belfast, UK. Briefly, 1 µg of RNA 
were converted to cDNA reverse-transcribed using the Superscript II First Strand 
cDNA synthesis kit (Life Technologies, USA) in a total volume of 19 µl. Quantitative 
Polymerase Chain Reaction (PCR) reactions were performed in triplicates for the 
following osteogenic genes: BMP1, BMP4, BMP6, COL1A1, TGFβ1, Osteonectin. 
2µl of cDNA, 10µl of SYBR Green PCR Master Mix (Applied Biosystems, USA) and 
1µl of 5µM primers formed the working solution which was topped up to a final 
volume of 20 µl. Thermal cycle conditions were 95°C for 10 min, then 45 cycles at 
95°C for 15 sec, and 60°C for 1 min. Amplifications were monitored with the ABI 
Prism 7000 (Applied Biosystems, USA). Results were normalised against the 
housekeeping gene β-actin, and relative gene expression analysed with the 2-ddCt 
method. The 5’-3’ forward (F) and reverse (R) primers of the respective genes are as 
follows: 
BMP1 F: ATCGACCTTGCGGCTCGGGA 
R: GCGACCCACGTAGGAGCAGC 
BMP4 F: GCCAAGCGTAGCCCTAAGC 
R: GTGGCGCCGGCAGTT 
BMP6 F: CGGTGCACTAGCCCCCTTCC 
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R: CTGCCCAGCAAACCCGCTCG 
COL1A1 F: CAGCTGCACCCCTACCACAGC 
R: CCCCACATCTCCCCTCTTCGCA 
TGFβ1 F: GGCAGTGGTTGAGCCGTGGA  
R: TGTTGGACAGCTGCTCCACCT 
Osteonectin F: CGCGGTCCTTCAGACTGCCC 
R: AGGCCCTCATGGTGCTGGGA 
 
3.10 Cellular Viability Assay  
Cellular viability in scaffolds was analysed by fluorescein diacetate/propidium iodide 
(FDA/PI) live/dead staining. The scaffolds/cells constructs were first incubated with 
4µg/ml FDA for 20 minutes at 37°C. The samples were then rinsed thrice in PBS, 
placed for 10 minutes in a 100µg/ml PI solution, rinsed again in PBS once and 
viewed under a confocal laser microscope. FDA stains viable cell cytoplasm green 
and PI stains necrotic and apoptotic cell nuclei red. Stained samples were then 
viewed under a confocal laser microscope. 
 
3.11 Growth Kinetics and Colony-Forming Unit-Fibroblasts Assay 
hfMSC were plated in well plates at 5000 cells/cm2 and allowed to proliferate in D10 
media under the appropriate oxygen tensions. Cells were trypsinised daily and their 
growth kinetics was assessed by enumerating the cell numbers using a 
haemocytometer (n=4). Colony-Forming Unit-Fibroblasts (CFU-F) assay was carried 
out by low density plating of hfMSC at 400 cells per 100mm dish (8 cells/cm2) in D10 
for 14 days, unless otherwise specified. The cells were then stained with 3% Crystal 
Violet in 100% methanol for 5 minutes at room temperature. Colonies ≥2 mm in 
diameter were counted. 
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3.12 Preparation of Cellular-Scaffold Constructs 
3.12.1 Scaffold Fabrication and Treatment 
Macroporous PCL/TCP (80/20) scaffolds (Osteopore International, Singapore) with a 
lay-down pattern of 0/60/120°, and porosity of 70% were fabricated using a fused 
deposition modelling technique under Current Good Manufacturing Practices (cGMP) 
environment (ISO 13485; Figure 3-1). Scaffolds were cut into 4X4X4mm dimensions, 
treated with 5M NaOH for 3 hrs to enhance hydrophilicity and washed thoroughly 
with PBS thrice prior to ethanol sterilisation. 
 
A.              B. 
 
Figure 3-1: (A) Macroscopic view and (B) SEM imaging of the PCL/TCP scaffolds 
shows a high porosity with an approximate pore size of 500µm and honeycomb 
microarchitecture. 
 
3.12.2 Cell Loading 
 
EPC/hfMSC (1:1) and hfMSC were suspended in Tisseel Fibrin Sealant (Baxter, 
Switzerland). Thrombin was first dissolved in calcium chloride solution, while Tisseel 
was dissolved in sterile water. Tisseel solution was then added to the scaffold prior to 
seeding the coculture/fibrin mixture into the porous scaffolds, keeping the hfMSC 
density constant (at 3,000 cells per mm3). Fibrin mixture was allowed to polymerise 





70% porosity with 
large porous size 
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3.13 Bioreactor Setup 
The bioreactor set-up was as previously described in Zhang et al (Zhang et al. 2009). 
Briefly, the biaxial bioreactor consists of a spherical culture chamber, where the 
cellular scaffolds are anchored to the cap of bioreactor by pins, a medium reservoir 
and a perfusion system, which connects culture chamber and medium reservoir. The 
spherical culture chamber is designed to rotate in two perpendicular axes (Y and Z, 
pink block arrows) simultaneously and perfused with media flow circulating between 
culture chamber and medium reservoir (Figure 3-2). The bioreactor was then placed 
into the incubator that was equilibrated to atmospheric oxygen tension. 
                      
Figure 3-2: The perfusion biaxial bioreactor has two rotational axes (indicated by 





3.14.1 Phase Contrast Light Microscopy 
Cellular morphology, adhesion and extracellular matrix production were examined by 
phase contrast light microscopy (PCLM) daily and imaged at fixed time intervals 












3.14.2 Confocal Microscope 
Monolayer and 3D cultures were viewed and scanned under a confocal laser 
microscope using laser wavelengths of 405nm (green), 594nm (red), 4',6-diamidino-
2-phenylindole (DAPI) channel (blue) (Olympus, FV300 Fluoview, Japan).  
3.14.3 Scanning Electron Microscope  
Glutaldehyde-fixed scaffolds were then dehydrated, air-dried and gold sputtered with 
SCD 005 gold sputter machine (Bal-Tec, Liechtenstein) for 70s at 30mA under high 
vacuum before imaging on the Scanning Electron Microscope (SEM) (JSM 5660, 
JEOL, Japan). 
3.14.4 Micro-Computed Tomography  
The cellular-scaffold constructs were fixed in 10% formalin for one week prior to 
analysis of bone or vasculature network using the Micro-CT scanner (SMX-100CT X-
ray CT Sys, Shimadzu, Japan). The scan settings were: X-ray voltage=45kV, X-ray 
current=100uA, detector size=9”, scaling coefficient=50 and voxel resolution=0.008 
mm. The scans were then reconstructed using VGStudioMax (Version 1.2, Volume 
Graphics, Germany) to create the 3D geometry and for quantitative 
histomorphometric analysis, with threshold values calibrated against its background.  
 
3.15 Animal Work 
3.15.1 Subcutaneous Implantations in Mice 
Under general anaesthesia, cellular-scaffold constructs were implanted into 
subcutaneous pockets generated at the dorsal surface of each immunodeficient 
NOD/SCID mouse (Figure 3-3), and the skin closed with 5-O Vicryl sutures. 




Figure 3-3: Diagrammatic representations of scaffold-constructs upon subcutaneous 
implantations at the dorsal surface of the NOD/SCID mice. 
 
3.15.2 Microfil Perfusion  
Visual observation of vascularisation was performed with the use of a vascular 
contrast, Microfil (MV-120, Flow Tech, USA). Briefly, mice were anaesthetised, laid 
supine and heparinised with 0.1ml of 500U via the tail vein before making a midline 
incision extending across the thorax and abdomen. Their left ventricles were 
cannulated and a perforation was made in the right atrial appendage before 
perfusion with 50ml of 10U heparinised saline. Upon exsanguination, 10ml of Microfil 
solution along with MV-curing agent (10% of total volume) were perfused via syringe.  
Animals were then stored at 4°C for 2h for the silicon compound to polymerise 
before scaffolds were harvested and fixed in 4% paraformaldehyde for a week prior 
to Micro-CT imaging (Zhang et al. 2010). 
3.15.3 Histology   
Cellular-scaffold constructs were placed on crushed dry ice for slow freezing, 
embedded in Optimal Cutting Temperature (OCT) compound and sectioned 
transversely with a Cryostat (CM 3050S, Leica, Germany). Sections of 50µm 






10µm thickness. Cryosections were then stained with Hematoxylin and Eosin stain 
(H&E) and Masson’s Trichrome (MT) to visualise tissue morphology and evidence of 
new bone formation. 
3.15.3.1 Capillary Density Analysis 
Capillaries were quantified by evaluating the entire area of histological sections. 
Luminal structures perfused with red blood cells were identified as a capillary. The 
capillary density was calculated by dividing the total number of red blood cell-filled 
capillaries by the area of each section (vessels/mm2).  
3.15.4 Immunohistochemistry 
3.15.4.1 Human:Mouse Chimerism 
Lamins A/C immunostaining was used to investigate chimerism of human cells in 
murine tissue. Cryosections from each sample were blocked with 5% normal goat 
serum for 1 hour, and left to react with monoclonal mouse anti-human Lamins A/C 
antibody (1:100, Vectorlabs, UK) overnight; sections were then incubated with goat 
anti-mouse secondary antibodies (1:100 Alexaflour 488, Life Technologies, New 
Zealand) for 1 hour, and counterstained with PI. Images were visualised using 
confocal microscopy.  
3.15.4.2 Staining of CD31 Structures 
Cryosections from each sample were blocked with 5% normal goat serum for 1 hour 
and left to react with monoclonal mouse anti-human lamin A/C (1:100, Vector 
Laboratories, U.K.), mouse anti-human CD31 (1:100, Millipore, USA), and rat 
antimouse CD31 (1:100, BD Pharmingen, USA) antibodies, respectively, overnight; 
sections were then incubated with goat anti-mouse secondary antibodies (1:100 
Alexafluor 488/594, Life Technologies, New Zealand) for 90 minutes and 
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counterstained with PI or DAPI mounting media. Images were visualised using 
confocal microscopy. 
3.15.4.3 Osteopontin Staining 
The contribution of human cells to in vivo bone regeneration was delineated with 
human specific osteopontin staining (1:100, Abcam, UK) as previously described 
(Zhang et al. 2010). 
3.15.5 Image Analysis 
3.13.5.1 ImageJ Software 
To enumerate the number of human and murine cells stained by Lamins A/C, 
ImageJ software was used to quantify the number of green and red staining in at 
least 3 different regions of the cryosections. 
3.15.5.2 Imaris Software 
Imaris was used to visualise the vessel formation from different angular perspectives 
as well as the vessel structures and cross sections at different depths.  
 
3.16 Statistical Analysis 
Parametric data are presented as mean ± standard deviation and were analysed by 
t-test or analysis of variance (ANOVA). “*” (p<0.05), “**” (p<0.01), “***” (p<0.001) 














Chapter 4 - Coculture of Human Umbilical Cord Blood Endothelial Colony-
Forming Cells with Human Fetal Mesenchymal Stem Cells for the  
Generation of Vascularised BTE Grafts 
If you can imagine it, you can achieve it; if you can dream it, you can become it. 
~William Arthur Ward 
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Chapter 4 – Coculture of Human Umbilical Cord Blood Endothelial Colony-
Forming Cells with Human Fetal Mesenchymal Stem Cells for the Generation of 
Vascularised BTE Grafts 
 
4.1 Abstract 
UCB-EPC show utility in neovascularisation, but their contribution to osteogenesis 
has not been defined. Cocultures of UCB-EPC with hfMSC resulted in earlier 
induction of ALP (Day 7 versus 10) and increased mineralisation (1.9 fold; p<0.001) 
compared to hfMSC monocultures. This effect was mediated through soluble factors 
in EPC-conditioned media, leading to 1.8-2.2 fold higher ALP levels and a 1.4-1.5 
fold increase in calcium deposition (p<0.01) in a dose dependent manner. 
Transcriptomic and protein array studies demonstrated high basal levels of 
osteogenic (BMPs and TGF-βs) and angiogenic (VEGF and Angiopoietins) 
regulators. Comparison of defined UCB and adult PB-EPC showed higher 
osteogenic and angiogenic gene expression in UCB-EPC. Subcutaneous 
implantation of UCB-EPC with hfMSC in immunodeficient mice resulted in the 
formation of chimeric human vessels, with a 2.2 fold increase in host 
neovascularisation compared to hfMSC-only implants (p=0.001). This study shows 
that UCB-EPC have potential in therapeutic angiogenesis and osteogenic 
applications in conjunction with MSC. It is speculated that UCB-EPC play an 
important role in skeletal and vascular development during perinatal development, 
but less so in later life when expression of key osteogenesis and angiogenesis genes 




Circulating EPC isolated from human PB have been implicated in the process of 
neovascularisation (Asahara et al. 1997) and investigated in various vascular 
paradigms. Numerous clinical trials using EPC have been performed, largely for 
treatment of limb ischemia (Tateishi-Yuyama et al. 2002) and myocardial infarction 
(Dimmeler and Zeiher 2009). However, unlike preclinical rodent models, only modest 
benefits have been observed; for example, left ventricular ejection fraction improved 
only 2-8%, with no reduction in death or stroke (Dimmeler and Zeiher 2009). A major 
problem confronting this field is the inconsistency in defining what constitutes an 
EPC, with the use of CD34+, CD133+ and VEGFR2+ among others as markers of 
EPC, leading to high levels of contamination with haemopoietic stem and progenitor 
cell types, and few studies providing evidence of functional differentiation in vitro or 
in vivo (Richardson and Yoder 2011). Furthermore, few protocols exist which can 
reliably expand these putative EPC into clinically-useful numbers. 
 
Recently, the use of a stringent culture system for deriving PB or UCB-EPC has 
allowed the reliable isolation and expansion of cells which are clonogenic, have a 
well-defined immunophenotype and the ability to engraft functionally as blood 
vessels in murine models  (Yoder et al. 2007; Richardson and Yoder 2011). These 
EPC are relatively pure and uncontaminated by haemopoietic lineages, being CD45 
negative, and can be reliably isolated and expanded, raising the possibility of their 
use in regenerative medicine.  
 
In previous work, the superiority of hfMSC over other MSC sources for generation of 
highly osteogenic tissue-engineered bone grafts utilising bioresorbable 
osteoinductive macroporous scaffolds has been shown (Zhang et al. 2010). Here, I 
propose the use of EPC in coculture with hfMSC to generate an osteogenic graft with 
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enhanced vasculogenic potential. This study will be of relevance to not only bone, 
but to other fields of tissue engineering where voluminous grafts are required. 
 
4.3 Experimental Approach  
In this project, the interactions of well-characterised UCB-EPC with hfMSC are 
examined through a series of in vitro and in vivo transplantation assays, with the 
overall goal of defining the use of EPC in the generation of vascularised grafts. 
 




4.4.1 Cell Characterisation 
4.4.1.1 Human Fetal Mesenchymal Stem Cells  
hfMSC have a spindle morphology and underwent tri-lineage differentiation into 
adipogenic, chondrogenic and osteogenic lineage when differentiated in their 
respective media (Figure 4-1A). The cells were screened by flow cytometry, where 
the histogram of the cells stained with the marker of interest (green plots) was 
overlaid with that of the unstained cells (control; red plots). Plots that laid within the 
region of the control group were considered negative for the marker of interest, 
whereas those that laid towards its right indicated positive staining for the marker of 
4 days BM 
Cell suspension loaded  
onto 4x4x4mm scaffolds  
Subcutaneous 
implantation in mice 
3, 8 weeks 
Assays 
Cells mixed in fibrin  Coculture 
Media Ratio Mechanism 
Transcriptome Protein 
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interest. Here, hfMSC were found to be negative for haemopoietic and endothelial 
markers (CD34, CD45 and CD31), expressing low levels within the range of ~1%. 
MSC markers such as CD73, CD105, CD90 were positive and showed a high level 
of expression (Figure 4-1B).  
 
A. Phase Contrast Microscopy 










Figure 4-1: (A) hfMSC had a spindle-like morphology and underwent tri-lineage 








vacuoles of neutral fat; Alcian Blue staining showed the presence of 
glycosaminoglycan in cartilages upon culture in a micro-mass pellet form; von Kossa 
stains (black) for extracellular calcium deposition. (B) Immunophenotypic 
characterisation of hfMSC using flow cytometry showed high expression of MSC 
markers such as (A-C) CD73, CD90, CD105 and did not express hematopoietic and 
endothelial markers such as (D-F) CD14, CD34 and CD45. 
 
4.4.1.2 Endothelial Progenitor Cells 
UCB-EPC emerged as polygonal cells in a cobblestone pattern and differentiated 
into tube-like networks when plated on Matrigel. Their immunophenotypic 
characteristics were demonstrated by its expression of DiI acLDL uptake, CD31, 
vWF and VE Cadherin, with cell nuclei counterstained with PI and DAPI accordingly 
(Figure 4-2) (Chong et al. 2009). 
PCLM Matrigel DiI acLDL 
CD31 vWF VE Cadherin 
  
 
Figure 4-2: Characterisation of UCB-EPC. (Top row from left to right) PCLM of EPC 
demonstrated typical cobblestone morphology of endothelial cells. EPC differentiated 
and formed networks when plated on Matrigel. Immunostaining demonstrated 
expression of (Bottom row from left to right) CD31, von Willebrand Factor, acLDL 
uptake (red) and VE Cadherin, indicating endothelial phenotype and function. Cell 
nuclei were counterstained with PI (red) and DAPI (blue) accordingly. 
 
100µm 100µm 
100µm 100µm 100µm 




4.4.2 Optimal Media for Osteogenic Differentiation of Coculture In Vitro 
To determine suitable culture conditions for stimulating osteogenic differentiation, 
EPC and hfMSC were cultured separately in BM, EGM10 and EGM10 supplemented 
with bone inducing elements (b-EGM10). Various media types and their composition, 
as well as the rationale for their use in this study are summarised in Table 4-1. 
 
Table 4-1: The different media types and their respective constituents are used for 
identifying the optimal media for directing osteogenic differentiation of the coculture.  
Media Media components Rationale for use 
BM • DMEM + 10% FBS 
• Bone inductive 
components 
(glycerophosphate, dexa-
methasone, ascorbic acid) 
• Well-defined media for osteogenic 
differentiation 
• Intended as a control group 
EGM10 • EBM + 10% FBS 
• Bullet kit of growth factors 
(EGF, bFGF, VEGF, IGF) 
• EGM10 to maintain cellular viability 
of EPC 
• Intended as a control group 
b-EGM10 • EBM + 10% FBS 
• Bullet kit of growth factors 
• (EGF, bFGF, VEGF, IGF) 
• Bone inductive component 
(glycerophosphate, dexa-
methasone, ascorbic acid) 
• EGM10 to maintain cellular viability 
of EPC 
• Bone inductive components to direct 
osteogenic differentiation  
 
Only BM, and not EGM10 or b-EGM10 induced osteogenic differentiation of hfMSC, 
seen as extracellular crystals under PCLM (Figure 4-3A), and confirmed by Von 
Kossa staining (Figure 4-3B). Quantitatively, BM induced high levels of calcium 
deposition in hfMSC (24.1µg/well), but not in EPC (0.1µg/well; p<0.001) cultured in 
BM, while no calcium was deposited in either cell type when cultured in EGM10 or b-
EGM10 (Figure 4-3C).  
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B. Von Kossa Staining            
 
 





























Figure 4-3: BM is necessary to induce osteogenic differentiation of hfMSC. (A) 
hfMSC laid down extracellular minerals when cultured in BM, while cell debris was 
observed with EPC in BM. Cells cultured in EGM10 and b-EGM10 did not 
demonstrate mineralisation. (B) hfMSC cultured in BM showed dark Von Kossa 
stains for calcium crystals but none in the other study groups. (C) This was 
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confirmed by quantitative calcium assays with only hfMSC grown in BM laying down 
significant amounts of calcium. All assays were performed on Day 14. 
 
4.4.3 Optimal Coculture Ratio for Osteogenic Differentiation In Vitro 
To determine the optimal cell-ratio for osteogenic induction, EPC and hfMSC were 
cocultured at different ratios but a constant hfMSC seeding density (20,000 
cells/cm2). Cocultured EPC/hfMSC resulted in earlier mineralisation compared to 
hfMSC alone, with extracellular crystals seen by Day 4 in coculture groups compared 
with Day 7 in hfMSC-only cultures (Figure 4-4A). EPC/hfMSC cocultured in a 1:1 
ratio achieved the earliest ALP peak on Day 7 compared to other groups (Figure 4-
4B), and a 1.9 fold higher calcium deposition on Day 14 compared to hfMSC cultures 




A. Phase Contrast Microscopy 





























































B. Alkaline Phosphatase Assay         























C. Calcium Content Assay 





























Figure 4-4: EPC/hfMSC in coculture induces earlier osteogenic differentiation of 
hfMSC. (A) EPC/hfMSC groups in varying ratios displayed earlier mineralisation 
compared to EPC and hfMSC monocultures. (B) Quantitative ALP measurements 
with EPC/hfMSC (1:1) demonstrated the earliest ALP peak activity on Day 7. (C) 
EPC/hfMSC (1:1) cocultures laid down the most calcium on Day 14. “***” (p<0.001).  
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4.4.4 Mechanism of Action of EPC for Osteogenic Potentiation 
To investigate the mechanism for the observed osteogenic enhancement of hfMSC, 
EPC conditioned media (EPCCM) was added directly into hfMSC cultures. This 
resulted in more extracellular crystals being deposited than in hfMSC cultured in BM 
alone, as seen on light microscopy (Figure 4-5A). This was confirmed by increased 
von Kossa staining on Day 14 in EPCCM (1:1) and EPCCM (1:10) cultures compared to BM 
cultures (Figure 4-5B). Quantitatively, ALP activity peaked earlier in the EPCCM (1:1) 
group at Day 7 compared to Day 10 for EPCCM (1:10) and BM groups, with peak values 
being 2.2 and 1.8 fold higher when cultured in EPCCM (1:1) and EPCCM (1:10) 
respectively compared to BM (Figure 4-5C). Correspondingly, 1.3 fold more calcium 
was deposited in the EPCCM (1:1) compared to BM by Day 14 (p<0.05) (Figure 4-5D). 
Collectively, these results suggest that soluble factors secreted by EPC play a role in 
potentiating osteogenic differentiation of hfMSC in a dose dependent manner.  
Next, I assessed the ability of EPC themselves in the absence of bone inducing 
components to induce osteogenic programming of hfMSC upon direct contact. 
hfMSC and EPC/hfMSC groups cultured in BM showed 2 (p<0.01) and 2.5 fold 
(p<0.001) higher ALP activity respectively compared to culture in basal D10 media 
(Figure 4-5E). Similarly, calcium deposition was found only in BM cultures, but not 
D10 cultures for either hfMSC and EPC/hfMSC as assayed by Von Kossa staining 
and quantitated (Figure 4-5F-G), suggesting that the addition of EPC to hfMSC in 
basal D10 media does not induce osteogenic programming in hfMSC, but rather, 
EPC potentiates osteogenic differentiation of hfMSC cultured in BM.  
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C. Alkaline Phosphatase Assay (CM)       
















D. Calcium Content Assay (CM) 
































































































G. Von Kossa Staining 
hfMSC in D10 hfMSC in BM EPC/hfMSC in D10 EPC/hfMSC in BM 
    
 
Figure 4-5: Dose dependent effect of soluble factors in EPCCM enhanced osteogenic 
differentiation of hfMSC. (A) hfMSC cultured in EPCCM (1:1) and EPCCM (1:10) 
demonstrated earlier and more extensive mineralisation than when cultured in BM. 
(B) Greater Von Kossa staining were observed in EPCCM (1:1) and EPCCM (1:10) 
compared to BM at Day 14 of osteogenic differentiation. (C) EPCCM (1:1) and EPCCM 
(1:10) displayed higher (2.2 fold and 1.8 fold respectively) peak of ALP activity than BM. 
(D) Calcium deposited in EPCCM (1:1) and EPCCM (1:10) was consistently higher (1.5 fold 
and 1.4 fold respectively) than BM in all time points. (E) ALP levels were consistently 
higher in BM than in basal media, D10, with the coculture displaying highest levels 
on Day 14. (F) Both hfMSC and EPC/hfMSC cocultures required osteogenic 
supplements to induce osteogenic differentiation, which was potentiated with 
coculture, with deposition of calcium after 14 days of induction, further confirmed by 
Von Kossa staining (G). “***” (p<0.001) 
 
 
4.4.5 Identity of EPC Secretome 
Two approaches were adopted to interrogate the identity of secreted proteins in 
EPCCM responsible for the enhanced osteogenic differentiation of hfMSC. Firstly, I 
100µm 100µm 100µm 100µm 
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used a transcriptomic approach to find that EPC highly expressed a range of genes 
associated with angiogenesis, as well genes associated with osteogenesis such as 
members of the TGF-beta pathway including SMAD1,2,3 and 5 and Bone 
Morphogenetic Proteins, BMP-1,2,3,6,7 and 8 (Supplementary Table S1A-B, 2-3).  
 
Next, a semi-quantitative antibody array (Figure 4-6) was used to assay the 
secretome of EPC found in EPCCM. EPC secreted several inflammatory cytokines, 
angiogenic factors, as well as bone-related proteins, all of which play an important 
role in regulating the biological processes involved in fracture healing. High levels of 
secreted proteins such as Angiogenin, Ang-2, GRO, IL-6, IL-8, MCP-1, MIP-3a, 
PDGF-BB and TIMP-2 were identified (Table 4-2). In addition, I confirmed the 
transcriptomic observations identifying bone related proteins, BMP-5, BMP-6, BMP-7, 
TGF-b1, TGF-β2 from the TGF-β superfamily secreted into EPCCM. These, along 
with bFGF, Endoglin, FGF-4, IGF-1, MCP-1, Oncostatin, Osteoprotegerin, PDGF and 
VEGF found in the EPCCM, may have contributed directly or indirectly to the 
observed enhancement in osteogenesis (Supplementary Table S4).  
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A. Human Cytokine Antibody Array 




Figure 4-6: Semi-quantitative analysis of EPCCM using the Human Cytokine Antibody 
Array, where 118 secreted proteins found within EPCCM. 
 
Table 4-2: (A) Top highest concentration of proteins found within EPCCM, of which 
angiogenic cytokines and other (B) bone related morphogens belonging to the TGF-
β superfamily are featured prominently.  
 
A. Secreted Proteins in High Concentrations in EPCCM    


























4.4.6 Osteogenic and Angiogenic Capacity of UCB versus PB-EPC  
To validate this, transcriptomic data from a previously-published study was 
reanalysed. The effect of EPC on osteogenesis and angiogenesis processes was 
reported separately for well characterised UCB-EPC and adult PB-EPC (Figure 4-
7A) (Medina et al. 2010). Results showed that UCB-EPC expressed BMP-1 (4.1 fold), 
BMP-2 (2.9 fold), BMP-4 (2.4 fold), BMP-6 (1.5 fold), TGF-β2 (11.0 fold) and 
COL1A1 (2.4 fold) among others at higher levels than in adult PB-EPC. By using 
different samples of UCB (n=1) and adult PB-EPC (n=2), I validated some of these 
genes through quantitative PCR to show that BMP1, BMP4, BMP6, COL1A1, TGFβ1 
and osteonectin were upregulated in UCB over adult PB-EPC (Figure 4-7B). 
Similarly, UCB-EPC expressed key angiogenesis genes at higher levels (Figure 4-
7A and Supplementary Table S5-6).  
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A. Microarray Analysis 
 








































Figure 4-7:  UCB versus adult PB-EPC taken from Medina et al (Medina et al. 2010) 
demonstrated higher expression levels of key osteogenic and angiogenic genes 
using (A) Transcriptomic microarray analysis and (B) qPCR. 
 
 
4.4.7 In Vitro Vessel Forming Ability of EPC/hfMSC Cocultures 
By labelling EPC with GFP, a poor viability of EPC when cultured in D10 over 14 
days was observed, whereas the addition of the standard osteogenic inducing 
agents dexamethasone, ascorbate and β-glycerophosphate, improved their viability 
markedly (Figure 4-8A). Coculture of GFP-labelled EPC with nuclear RFP-labelled 
hfMSC, resulted in formation of EPC-derived islets which evolved by Day 7 into tube- 
like structures when cultured in BM, but not when cultured in D10 (Figure 4-8B).  
 
Next, I looked at the ability of this coculture system to induce tube-like structures in a 
3D culture system within a macroporous scaffold. Cocultured GFP-EPC and hfMSC 
embedded in fibrin and loaded onto these scaffolds proliferated and occupied the 
porous scaffold over time, with complex tubular structures with multiple branch-points 
seen throughout the scaffold by Day 14 (Figure 4-8C). 
 107 
A. Viability of EPC Cultures in BM and D10 in 2D 















    
 
B. Confocal Imaging of Coculture Distribution in 2D 




























C.  EPC Vascular Network in Coculture with hfMSC in 3D at Day 14 of In Citro 
Culture 
   
Figure 4-8: EPC potentiate osteogenic programming of hfMSC and in vitro tubule 
formation in the presence of bone inducing components (A) GFP-labelled EPC 
showed better survival when cultured in BM than in D10. (B) Coculture of GFP-EPC 
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and H2B-RFP-hfMSC (Red fluorescence nuclear staining) resulted in the formation 
of EPC islets (white arrowheads), leading eventually to the development of tubular 
structures (yellow arrows) by Day 7 (C) Formation of GFP-EPC vessel-like structures 
with complex branching points was observed when EPC/hfMSC were cocultured 
over 14 days within a 3D culture system within a macroporous scaffold.  
 
4.4.8 In Vivo Vasculogenesis of EPC/hfMSC Cocultures 
Following the robust formation of vascular structures within 3D EPC/hfMSC 
cocultures in vitro, I implanted EPC/hfMSC and hfMSC-loaded scaffolds 
subcutaneously into immunodeficient mice (Figure 3-3). Three weeks after 
implantation, perfusion of a vascular contrast agent showed an extensive network of 
vessels surrounding the harvested EPC/hfMSC scaffolds, while comparatively few 
vessels were seen on hfMSC-only scaffolds (Figure 4-9A).  
 
By Week 8, human CD31 positive blood vessels with complex networks could be 
seen coursing through EPC/hfMSC scaffolds but not hfMSC-only scaffolds (Figure 
4-9B). These human vessels were seen to form chimeric vessels, joining with host-
derived vessels stained with murine-specific CD31 antibodies (white arrows in 
Figure 4-9C) at multiple levels throughout the scaffold (Figure 4-9B-C). By staining 
for murine specific CD31 positive blood vessels (red), EPC/hfMSC scaffolds were 
found to develop 2.2 fold greater area of murine-specific CD31 per µm2 than hfMSC-
only scaffolds (p=0.001), suggesting a higher degree of host-derived 
neovascularisation (Figure 4-9D). In EPC/hfMSC scaffolds, human vessels 
accounted for 30.2% of all vessels within the scaffold core (Figure 4-9E). This 
observation was supported by a lower degree of human cell chimerism in the 
EPC/hfMSC scaffolds compared to hfMSC-only scaffolds (55.9±4.7 versus 
74.8±12.3%, p>0.05) (Figure 4-9F), and may reflect a higher degree of host-derived 


















B. Human and Mouse Specific CD31 Vessel Networks in Scaffolds 
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C. Cross Sectional View of Slide  
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E: Quantification of Human and Murine Vasculature in EPC/hfMSC Scaffolds 
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F. Human : Mouse Chimerism 
 
EPC/hfMSC hfMSC  
55.9±4.7% 74.8±12.3% 
 
Figure 4-9: In vivo neovasculogenesis and ectopic bone formation. A) Increased 
vascularisation of the EPC/hfMSC scaffolds evident three weeks after implantation, 
as seen after Microfil perfusion (blue vessels). (B) At eight weeks, human blood 
vessels stained with human specific CD31 (green) were seen coursing through 
EPC/hfMSC scaffolds but not hfMSC scaffolds. These human vessels can be seen 
enmeshed with murine vessels (stained red with murine CD31 antibody) as evident 
in a 50 µm section [merged and stacked confocal images (C)].  EPC/hfMSC 
scaffolds contained a 2.2 fold (p=0.001) higher density of host-derived murine-CD31 
positive vessels (red) compared to hfMSC scaffolds (arrows indicating area of 
human-murine vasculature junctures) (D), while human vessels constituted 30.2% of 
the total vessel area within the construct (E). (F) Immunostaining with human Lamins 
A/C demonstrated high levels of chimerism in both scaffolds, with a trend towards 
lower human cell chimerism in EPC/hfMSC scaffolds compared with hfMSC scaffolds.  
 
4.4.9 Ectopic Bone Forming Ability of EPC/hfMSC Cocultures 
Von Kossa staining revealed darker staining in EPC/hfMSC scaffolds (Figure 4-10A), 
suggesting greater osteogenic differentiation was induced in the cocultured scaffolds. 
This was verified by the calcium quantification which showed a trend towards greater 
ectopic bone formation in the coculture group (Figure 4-10B), implicating the 
increased vascularisation in enhancing osteogenic differentiation in vivo. 
 






































Figure 4-10: (A-B) Von Kossa staining of the implants showed darker level of 
staining (Scaffold regions has been denoted as S) and a slightly higher level of 
calcium deposited in EPC/hfMSC scaffolds compared to hfMSC scaffold.  “*” (p<0.05) 
 
4.5 Discussion  
Several groups have cocultured putative EPC with MSC or osteoblast-like cell types 
on the premise that this strategy will generate prevascular networks within bone 
tissue-engineered grafts to aid bone repair (Fuchs et al. 2007; Melero-Martin et al. 
2008; Fuchs et al. 2009; Usami et al. 2009; Seebach et al. 2010; Tsigkou et al. 2010). 
However, the majority of studies used EC (Kaigler et al. 2005; Unger et al. 2007; 
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Unger et al. 2010; Koob et al. 2011; Saleh et al. 2011), rather than EPC. In this 
project, well-characterised UCB-EPC were cocultured with hfMSC (Zhang et al. 
2009) chosen primarily for their ability to undergo a well-defined osteogenic 
differentiation pathway (Frank et al. 2002; Guillot et al. 2008; Zhang et al. 2009) and 
superiority in osteogenic differentiation over adult counterparts (Guillot et al. 2008; 
Zhang et al. 2009) for bone tissue engineering applications. I unexpectedly found a 2 
fold enhancement in the osteogenic differentiation of hfMSC when cocultured with 
UCB-EPC, and showed that this effect was at least in part through paracrine 
signalling involving secreted members of the TGFβ superfamily. In addition, the 
addition of UCB-EPC to hfMSC led to the formation of tube-like network of 
endothelial structures in vitro, with the generation of chimeric human-murine blood 
vessels and enhancement of host-neovascularisation in vivo. Further, I provided 
evidence that there is an ontological advantage in skeletal morphogenesis and 
angiogenesis of the more primitive UCB derived EPC over adult sources.  
 
EPC were first identified in peripheral blood (Asahara et al. 1997) and subsequently 
isolated from other sources including bone marrow, fetal liver and umbilical cord 
blood (Richardson and Yoder 2011). However, the isolation of EPC from umbilical 
cord blood is still favoured over other sites due to its plentiful supply and non-
invasive collection process. In addition, EPC in UCB are found at higher frequencies 
and have higher proliferative and vasculogenic capacity than adult PB-EPC (Ingram 
et al. 2004).   
 
Studies of EPC have largely focused on their vasculogenic potential, with evidence 
of efficacy in augmenting neovascularisation in several different ischemic models. 
Recently, there has been increasing interest in the use of EPC populations for bone 
repair in mice (Matsumoto et al. 2008), rat (Atesok et al. 2010) and ovine models 
(Rozen et al. 2009). The key finding was a potentiated osteogenic response of 
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hfMSC in vitro via paracrine signaling, where soluble factors present in EPC 
conditioned media exerted a profound effect on osteogenic differentiation of hfMSC. 
The probable mechanism mediating the enhanced osteogenic effect is likely to be 
soluble factors secreted by EPC when cocultured in BM, given the lack of osteogenic 
induction when the coculture was performed in basal hfMSC growth media. Bone 
inductive components in BM could have been responsible for inducing osteo-
inductive secretions in EPC as detected by the protein array blot which identified a 
milieu of secreted factors present in EPC conditioned media, with negligible levels of 
these proteins found in BM alone (data not shown). The bone-related morphogens 
detected included BMP-5, BMP-6, BMP-7, TGF-β1, TGF-β2, which are known key 
facilitators or inductors of osteogenic programming in MSC. BMPs and TGFβs of the 
TGFβ superfamily are produced by osteoblasts and other bone cells incorporated 
into mineralised matrix, thus contributing to osteoblast differentiation in vitro (Cho et 
al. 2002). In vivo, such growth factors participate actively in various stages of 
intramembranous and endochondral bone ossification for bone formation and 
remodelling (Reddi 1981). In particular, the potent osteo-inductive abilities of BMPs 
have been widely demonstrated in various animal and clinical studies (Luginbuehl et 
al. 2004) and more recently, BMP-2 has also been used as an adjunct to the 
standard of care in the BMP-2 Evaluation in Surgery for Tibial Trauma (BESTT) 
study involving 450 patients with diaphyseal open tibial fractures (Nordsletten 2006). 
Despite the low relative levels of BMP detected, EPC conditioned media was still 
able to induce a significant increase in osteogenic differentiation of MSC in a dose-
dependent manner. In addition, VEGF detected in EPC conditioned media may have 
contributed significantly to the observed phenomena. VEGF has been reported to 
induce ALP activity in osteoblasts (Midy and Plouet 1994) and enhance osteoblast 
differentiation (Deckers et al. 2000). Behr et al also demonstrated that VEGF-A 
promotes osteogenic and endothelial differentiation (Behr et al. 2011), thus playing a 
significant role in skeletal repair (Peng et al. 2002). Other bone-morphogenic factors 
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such as FGFs, PDGF, oncostatin M, and endoglin have also been reported to induce 
osteoblast differentiation. The effects of multiple osteogenic factors secreted by EPC 
could have acted in synergy to enhance the potency of osteogenic differentiation of 
MSC, leading to the strong enhancement in mineralisation observed in vitro.  
 
Few groups have investigated the mechanism behind these enhanced osteogenic 
effects. Dohle and colleagues, through a study of primary osteoblast and adult 
peripheral blood late endothelial outgrowth cocultures implicated the sonic hedgehog 
(Shh) pathway as a key modulator in EPC-enhanced osteogenesis through 
supplementation of Shh and its inhibitor (Dohle et al. 2010). Saleh et al in 
demonstrating enhanced proliferation and osteogenic differentiation of human MSC 
exposed to conditioned media from HUVECs alluded to the possibility of FGF, Wnt, 
BMP and Notch pathways as possible regulators of this phenomenon (Saleh et al. 
2011), albeit without identifying these putative regulators directly. Wang and 
colleagues showed that cocultured HUVECs augmented osteogenic differentiation of 
adipose-derived MSC, with BMP-2 being identified in HUVEC conditioned media, 
although they did not test its paracrine activity (Wang et al. 2011).  In contrast to my 
suggested mechanism of paracrine signalling, several other groups failed to show 
osteogenic enhancement when MSC were cultured in the conditioned media of 
endothelial cells (Villars et al. 2000), instead suggesting direct cell-cell contact via 
gap junction communication was required to mediate the osteogenic enhancement 
effect (Villars et al. 2002; Kaigler et al. 2005). These groups however, employed 
mature human endothelial cells in coculture with osteoblast-like cells, which although 
they have shown promise in generating a prevascularised network (Tsigkou et al. 
2010; Unger et al. 2010) and/or enhancing osteogenesis (Villars et al. 2000; Villars et 
al. 2002; Kaigler et al. 2005; Rouwkema et al. 2006; Grellier et al. 2009; Koob et al. 
2011), their biologically phenotype depends upon the site of the endothelium from 
which they were harvested from (Aird 2007).   
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The use of BM to stimulate osteogenic differentiation of MSC, while maintaining high 
survivability of EPC without altering phenotypic stability (Fuchs et al. 2007) is 
essential for the observed enhanced osteogenic differentiation. EPC survived in 
monoculture at high levels of confluence in BM while maintaining their cobblestone 
morphology in the absence of any standard endothelial growth factors supplements 
(VEGF, EGF, bFGF, IGF-1, ascorbic acid, hydrocortisone and heparin). This is likely 
due to the presence of dexamethasone in BM, a potent synthetic glucocorticoid 
critical for EPC survival as an alternative to the hydrocortisone supplemented in 
EGM. In contrast to my findings, others have suggested that growth factor 
supplements are necessary to sustain EPC survival. Usami and colleagues attributed 
the difficulties of coculturing EPC and MSC in direct contact to the inability of EPCs 
to survive in osteogenic media, and resorted to culturing the cells on Polylactide-
coated collagen fiber mesh separately in their respective growth media prior to 
coimplantation in vivo (Usami et al. 2009). Other similar studies maintained 
cocultures in EGM instead (Fuchs et al. 2007; Fuchs et al. 2009; Rouwkema et al. 
2009). In this study, UCB-EPC were unable to induce osteogenic differentiation on 
hfMSC in the absence of bone inductive components of dexamethasone, ascorbate 
and β-glycerophosphate.  
 
By comparing the transcriptome of well-defined EPC populations derived from 
primitive UCB with mature adult PB-EPC from a previous study (Medina et al. 2010), 
both osteogenic and vasculogenic genes were significantly more expressed in UCB 
compared to adult PB-EPC. While the higher vasculogenic potential of UCB-derived 
EPC is largely expected, the higher expression of osteogenesis-related genes here 
may reflect the intense skeletal development occurring during neonatal life as 
compared to the mature adult. These circulating EPC are found at higher frequencies 
during neonatal life compared to adult life (Murohara et al. 2000), with increased 
mobilisation in the event of bony injury (Laing et al. 2007; Fujio et al. 2011). 
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In cocultures, EPC organised into islets that with decreasing cluster sizes from Day 7 
onwards, formed tubular structures which increased branching complexity over time 
during MSC coculture, while on their own, EPC monocultures were unable to form 
vascular networks on a collagen matrix. Establishment of more complex vessel-like 
networks was seen when EPC/hfMSC were cocultured within 3D macroporous 
scaffolds in BM culture. This suggests that MSC have a critical support function on 
endothelial cell survival and sprouting in vitro, in agreement with findings from other 
groups (Au et al. 2008; Tsigkou et al. 2010). Subcutaneous implants of these 
coculture constructs in mice further supported the observations in vitro, with more 
extensive neovascularisation of the scaffolds at three and eight weeks post 
implantation compared to MSC alone. Human-murine chimeric vessels were seen on 
confocal sections and species-specific immunohistochemistry only in EPC/hfMSC 
cocultures, with human specific CD31 positive structures arranged in a lumen-like 
fashion. This finding is consistent with previous reports (Au et al. 2008; Melero-
Martin et al. 2008; Fuchs et al. 2009; Rouwkema et al. 2009; Unger et al. 2010).  
 
By probing the transcriptome and secretome of UCB-EPC, I identified several pro-
inflammatory and angiogenic cytokines, in particularly Angiogenin, Angiopoietin-2 
and PDGF-BB that were found in relatively high concentrations which could have 
contributed to this in vivo observation of increased angiogenesis. Inflammatory 
cytokines such as IL-1, IL-6 and TNF-α, and other angiogenic protagonists such as 
VEGF, bFGF, angiopoietins, PDGF-BB - angiogenin, IL-8, bFGF, FGF-4, TGF-β, 
VEGF (Kanczler and Oreffo 2008), have a direct stimulatory effect on angiogenesis 
in vivo. Such increase in vascularisation could make a direct contribution to bone 
formation, as evident in the increased ectopic bone formed in the EPC/MSC 
constructs, suggesting an interdependent relationship between vascularisation and 
bone formation. Usami et al found a 1.6 fold higher capillary score formation on both 
the surface and central regions of canine-EPC/MSC scaffolds, accompanied by a 1.3 
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fold increase in bone area regenerated in subcutaneous implants (Usami et al. 2009), 
while Seebach et al demonstrated increased early vascularisation in the first four 
weeks with improved bone regeneration and healing in a rat critical-sized femoral 
defect model after EPC/MSC implantation compared to MSC alone (Seebach et al. 
2010).  
 
4.6 Conclusion  
In addition to their vasculogenic potential, circulating EPC in late fetal/neonatal life 
have significant osteogenic-inducing capacity, which they effect through secretion of 
potent osteogenic regulators from the TGFβ superfamily. The interaction of UCB-
EPC with hfMSC allows both the generation of stable functional blood vessels and 
the direct potentiation of hfMSC osteogenic differentiation through secreted factors. 
These effects alone or in combination are likely to lend themselves towards 
applications in regenerative medicine and tissue engineering. 
 
 
 
 
 
 
 
 
 
 
 
 
 
